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ABSTRACT 
Pharmacokinetics of Neostigmine and Pyridostigmine in Man, by Akbar Dehghan 
Most methods used for the extraction of quaternary amines in biological fluids 
have been based on ion-pair extraction techniques. In this study, a sensitive 
and selective chromatographic procedure is described to measure the concen- 
tration of pyridostigmine, neostigmine and their major metabolites in the 
plasma and urine. The methods involve a preliminary selective ion-pair 
extraction of the unchanged drugs and their metabolites into dichloromethane 
and dichloromethane-acetone mixture respectively. Quantitation is possible 
down to 3 ng/ml for parent drugs and 50 ng/ml for the metabolites. The 
present work also described a modified procedure to measure neostigmine and 
pyridostigmine in plasma simultaneously, using a specially synthesized 
pyridostigmine analogue as a common internal marker. 
The plasma concentration of pyridostigmine was measured after three differ- 
ent doses of the quaternary amine (36.2 Ng/kg, 72.4 pg/kg and 144.8 )tg/kg) 
were given intravenously to twenty five surgical patients during anaesthesia. 
The relation between the plasma concentration of pyridostigmine and time 
was invariably expressed as a bi-exponential equation, and the data was 
interpreted in terms of a two compartment model. The slow disposition half- 
life of the drug was progressively prolonged as the dose of the drug was 
raised from 36.2 Ng/kg to 144.8 jig/kg. A similar increase in the half-life 
was observed in cross-over studies. The clearance of the quaternary amine 
was enhanced at intermediate dose (72.4 )xg/kg) but significantly reduced 
after high dose (144.8 pg/kg). It was suggested that these results may 
partially account for the observed differences in the duration of action 
of neostigmine and pyridostigmine in man. The dose of pyridostigmine used 
to reverse non-depolarizing neuromuscular block is 4-5 times greater than 
neostigmine. 
After intramuscular administration of neostigmine to five myasthenic patients, 
the plasma concentration of the drug declined monoexponentially from 21 ±2 no/ml 
to 9t1 ng/ml between 30 and 120 minutes and data was interpreted in terms of 
a one-compartment model. Estimates of the plasma half-life varied from 56.9 - 
100.1 minutes. 
The oral administration of pyridostigmine alone and of both neostigmine and 
pyridostigmine in two different groups of myasthenic patients, were also 
studied. There was a direct linear relation between area, under the plasma 
concentration - time curve and total daily dose of pyridostigmine in the 
first group of patients (r = 0.95), but no such observation was noticed in 
either all patients (two groups; r=0.15) or in the second group who were 
treated with both drugs (r =-0.08). It was suggested that there might be a 
drug-drug interaction between pyridostigmine and neostigmine during oral 
absorption. 
The relation between plasma levels of pyridostigmine to clinical evaluation 
of muscle power was examined in nine myasthenic patients during treatment 
with pyridostigmine in doses of 60 to 1080 mg per day. Five of the nine 
subjects demonstrated a trend towards a positive correlation and in two of 
them was this significant at pt0.05. In addition, the presence or absence 
of a possible correlation between muscle power and plasma concentration was 
not related to the duration of disease, additional prednisolone therapy or 
thymectomy. 
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PREFACE 
This thesis, comprising of 7 Chapters, presents the develop- 
ment of the techniques available to measure the concentration of 
neostigmine and pyridostigmine in human biological fluids and 
also a study of the pharmacokinetics of the drugs in man. In 
addition, clinical studies were carried out to investigate the 
relation of plasma levels of pyridostigmine to clinical effects 
in patients with myasthenia gravis. 
In the first Chapter, the known pharmacological properties 
and clinical use of quaternary ammonium compounds are discussed. 
An introduction to the mathematical expressions of pharmacokinetics 
and a review on previous methods available for the determination 
of quaternary ammonium compounds is described in Chapter 2. 
Chapter 3 includes the development of the techniques used in the 
present investigations. The studies of pharmacokinetics of pyrido- 
stigmine in surgical patients are presented in Chapter 4. In 
Chapter 5 the study of pharmacokinetics of neostigmine after 
intramuscular administration to myasthenic patients is described. 
Chapter 6 includes the study of pharmacokinetics and pharmacologic 
effects of pyridostigmine and neostigmine after oral administration 
in patients with myasthenia gravis. The main findings and con- 
clusions of this thesis are summarized in the final chapter. The 
appendices expand some experimental details and tabulated results 
not included elsewhere in the thesis. 
The investigation was carried out in the Pharmaceutical 
Chemistry section of the School of Pharmacy, Liverpool Polytechnic. 
I wish to express my appreciation to Dr. K. Chan for the consistent 
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advice and encouragement he has given me whilst supervising 
this work. I express my thanks also to Dr. T. N. Calvey for his 
advice and co-operation in providing human blood samples to carry 
out the studies in Chapter 4 and 5. I am indebted to 
Dr. D. M. Freeman and Dr. M. Hayward for permitting the study 
of patients admitted under their care and to the patients for 
their ready co-operation. 
I am grateful to Dr. Susan C. Davison and Dr. N. Hyman 
of the Radcliffe Infirmary, Oxford, for their joint effort in 
the study on clinical response and plasma pyridostigmine 
(Chapter 6). Finally, I would like to thank Dr. P. Deravi 
for his assistance in computer programming. 
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ANTICHOLINESTERASE AGENTS 
HISTORICAL BACKGROUND 
Drugs that inhibit or inactivate acetylcholinesterases 
(AChE) are called anticholinesterase (anti-ChE) agents and thus 
are potentially capable of producing effects equivalent to 
continuous stimulation of cholinergic fibres throughout the 
central and peripheral nervous system. In view of the wide- 
spread distribution of cholinergic neurons, it is not surprising 
that the anti-ChE agents as a group have assumed more extensive 
practical application as toxic agents, in the form of 
agricultural insecticides and potential chemical warefare "nerve 
gases" than as drugs, nevertheless, there are certain 
representatives that are clinically useful. (See Table 1-1). 
Prior to the Second World War, only "reversible" anti-ChE 
agents were generally known, of which physostigmine (eserine) 
is the outstanding example. Shortly before and during World 
War II a comparatively new class of highly toxic chemicals, the 
organophosphorus was developed, chiefly by Schrader, of 
I. G. Farbenindustrie. These were first used as agricultural 
insecticides and later as potential chemical warfare agents 
(Roelle 1975). The extreme toxicity of these compounds was 
found to be due to their "irreversible" inactivation of AChE, 
thereby exerting their effects for considerably longer periods 
than do the classical reversible inhibitors. Since the 
pharmacological actions of both classes of anti-ChE agents are 
qualitatively similar, they will be discussed as a group, and 
the important special features of the individual classes or 
compounds will be pointed out. 
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Physostigmine, the first known anti-ChE agent, is an 
alkaloid obtained from the Calabar or ordeal bean of Physostigma 
Venonosum Balfour, which is a perennial woody climber growing in 
tropical West Africa. The calabar bean, also known as Esere 
nut, chop nut, or bean Etu Esere, was once used by native tribes 
of West Africa as an ordeal poison in trials for witchcraft. 
It was brought to England in 1840 by Daniell who was a British 
Medical Officer stationed in Calabar. Early investigations of 
its pharmacological properties were induced by Christieson 
(1825), Fraser (1863), and Argyll-Robertson (1863). The pure 
alkaloid of physostigmine was isolated by Jobts and Hesse in 
1864, and named physostigmine and the following year Vee and 
Leven (Goldman, 1975) obtained the same alkaloid which they named 
as eserine. The alkaloid was used first as a therapeutic agent 
in 1877 by Laqueurs in the treatment of glaucoma. Polonovski 
and Polonovski (1923) and Stedman and Bargar (1925) elucidated 
the chemical structure (see Table 1.1) of physostigmine, and its 
synthesis was accomplished by Julian and Pikl., (1935). 
Interesting accounts of the history of physostigmine have been 
presented by Rodin (1947), Karczmar (1970) and Holmstedt 
(1972). 
As a result of the basic research of Stedman and associates, 
(1929a, 1929b) in elucidating the chemical basis of the activity 
of physostigmine, Aeschlimannand Reinard (1931) systematically 
investigated a series of substituted phenyl esters of alkyl 
carbamic acids. Neostigmine (see Table 1.1) a member of this 
series, was introduced into therapeutics in 1931 
for its 
stimulant action on the intestinal tract. It was reported 
independently by Remen (1932), and Walker (1935) to be 
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effective in the symptomatic therapy of myasthenia gravis. 
Additional anti-ChE agents that bear a general structural 
resembs. lance to neostigmine were introduced for the treatment of 
myasthenia gravis. Among these are pyridostigmine and 
ambenonium. Edröphonium, a drug of simpler structure and with 
an extremely brief duration of actionis used in the diagnosis 
and evaluation of the therapy of the same disease. 
It is interesting to note that the first account of the 
synthesis of a highly potent compound of the organophosptorUS _cin'ti- 
ChE series, tetraethylpyrophosphate (TEPP), was published by 
Clerment in 1854, ten years prior to the " Isolation of 
physostigmine. More remarkable still as Holmstedt (1963) 
pointed out, is the fact that the investigator survived to report 
on the compounds taste as a few drops of the pure compound placed 
on the tongue would be expected to prove rapidly fatal. During 
the synthesis and investigation of approximately 2,000 compounds, 
Schrader (1952) defined the structural requirements for 
insecticidal (and as learned subsequently, for anti-ChE) activity 2f 
compounds in this early series, parathion became the most widely 
employed insecticide of this class. The synthesis of several 
compounds of much greater toxicity than parathion such as Sarin, 
Soman and Tabun resulted (Schrader 1952), and these were used 
as nerve gases in chemical warfare. 
THE MECHANISM OF ACTION OF ANTI-ChE AGENTS 
The anti-ChE agents are among the relatively few drugs for 
which the mechanism of action can presently be described in 
precise molecular terms. This can be related directly to their 
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overall pharmacological effects and has led to the development 
of useful compounds capable of reversing the actions of anti- 
ChE agents. The interactions between most of the anti-ChE agents 
and the enzyme AChE differ primarily in quantitative respects 
from the reaction between AChE_and its normal substrate 
acetylcholine (ACh). 
From studies initiated by Wilson and Bergmann (1950) and 
extended by Wilson and others, it has been established that the 
active surface of the enzyme unit consists of two sites, an 
anionic and an esteratic site (see Figurei. l). At the anionic 
site (a negative charge probably of the free ionised carboxyl 
group of a dicarboxylic amino acid), the postively charged 
quaternary N atom of ACh is attracted by electrostatic forces, 
and bonding is enhanced by hydrophobic forces exerted on the 
N-methyl groups. 
The esteratic site consists of essentially two components 
located 2.5 and 5A respectively from the anionic site; a 
potentially acidic function (the hydroxy group of serine) and a 
nucleophilic group (the basic N of an imidazole group of histidine). 
The imidazole group by hydrogen bonding (see Figure 14) enhances 
the nucleophilic activity of the serine hydroxyl group, thus 
enabling it to inter act with the electron deficient carbonyl C 
atom of ACh. A covalent bond is formed with the production of 
an acetylated enzyme intermediate and the release of choline 
(Figurel"la. ). The electron deficient C atom of the acetyl 
group then undergoes nucleophilic attack by the oxygen atom of 
a water molecule. The acetyl enzyme complex is thus hydrolyzed 
and the products are the regenerated enzyme and acetic acid. 
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The rate constants in this reaction sequence are extremely 
high, thus the time required for the complete hydrolysis of one 
ACh molecule (the turnover time), is only 80 micro seconds 
(Wilson et al., 1960). 
The mechanisms of action of compounds that typify the three 
classes of anti-ChE agents are shown in Figure 1.1(b, c, d). 
Simple quaternary compounds, such as tetraetheyfammonium ion, 
inhibit the enzyme reversibly by combining with it only at the 
anionic site, and thus blocking attachment of the substrate. 
Much more potent reversible inhibitors, such as edrophonium, combine 
in addition with the imidazole nitrogen atom of the esteratic 
site by hydrogen bonding through the phenolic OH group (Figuret. lb). 
In all such cases, inhibition is rapidly reversible and such 
drugs have a very brief duration of action following systemic 
administration. 
It was at one time generally assumed that physostigmine, 
neostigmine and related potent inhibitors that possess a 
carbamyl ester linkage or urethane structure, in addition to a 
tertiary amino or quaternary ammonium group, inhibit the enzyme 
in the same reversible fashion. However, careful kinetic 
studies have since shown that only a negligible amount of an 
inhibitor of this type is released reversibly from the enzyme; 
actually, physostigmine and neostigmine are hydrolyzed extremely 
slowly by cholinesterases (Goldstein and Hamlish, 1952; 
Myers, 1952,1956; Wilson et al., 1960). It is likely that 
inhibitors of this class form complexes in which the inhibitor 
is attached to the enzyme at both the anionic and esteratic 
sites, following which their hydrolysis proceeds in a manner 
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analogous to that of ACh (Figurel. lc), the alcoholic moiety is 
split off, leaving a carbamoylated enzyme that reacts with water 
to release a substituted carbamic acid and regenerated enzyme. 
The main difference between the hydrolysis of the natural 
substrate, ACh, and the inhibitor, neostigmine, is the velocity 
of the final step, the half-life of dimethylcarbamoyl-AChE, 
formed by the reaction with neostigmine, is more than 40 million 
times that of the acetylated enzyme (30 minutes and 42 micro- 
seconds respectively, Wilson and Harrison 1961). Thus, these 
drugs and newer carbarnate insecticides are called "competitive 
substrates" or "acid transferring inhibitors" and can be 
distinguished from the simply reversible inhibitors described 
above. 
The reaction between AChE and most organophosphorous 
inhibitors such as di-isopropylphosphorofluoridate (DFP) occurs 
only at the estratic site, but proceeds in a comparable fashion 
(Figurel. ld). Here the resultant phosphorylated enzyme is 
extremely stable; if the attached alkyl groups are methyl or 
ethyl, significant regeneration of the enzyme by hydrolytic 
cleavage requires several hours; with isopyr. opyl groups, as in 
the example given, virtually no hydrolysis occurs and the return 
of AChE activity is dependent upon synthesis of new enzymes, 
a process requiring days to months. 
From the foregoing account it is apparent that the terms 
"reversible" and "irreversible" as applied to the carbamoyl 
ester and organophosphorous anti-ChE agents respectively, reflect 
only quantitatively differences and that both classes of drugs 
react with the enzyme in essentially the same manner as does ACh. 
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THE CHEMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIP OF SOME 
REVERSIBLE CARBAMATE INHIBITORS. 
Drugs of this class that are of therapeutic interest are 
shown in Table 1-1. After the structure of physostigmine was 
established, Stedman (1929a, 1929b) undertook a systematic 
investigation of a number of related synthetic compounds. 
They concluded that the essential moiety of the physostigmine 
molecule was the methyl carbamate of a basically substituted 
simple phenol (Table 1-1). The qua: -ternary ammonium 
derivative, neostigmine, is a compound of greater stability and 
equal or greater potency. The simple analogues of neostigmine 
that lack the carbamoyl group, such as edrophonium, are less 
potent and much shorter acting anti-ChE agents, since they 
produce a truly reversible inhibition as described above. 
Retention of the dimethycarbamate side chain in the meta 
position of phenol with the incorporation of the quaternay N atom 
within the ring to form a pyridinium nucleus results in compounds 
with anti-ChE and pharmalogical properties similar to those of 
neostigmine. Pyridostigmine, a drug of this classý)is used 
in the treatment of myasthenia gravis. 
A marked increase in anti-ChE potency and duration of 
action can result from linking of two quaternary ammonium nuclei 
by a chain of appropriate structure and length. one such example 
is the miotic agent demecarium, which consists of two neostigmine 
molecules connected at their carbamate nitrogen atoms by a series 
of ten methylene groups. It is likely that this compound 
combines with the anionic and esteratic sites of two adjacent 
AChE units within the same tetramer just as the bis-quaternary 
-14- 
COMPOUND STRUCTURAL FORMULA 
(a) TERTIARY AMINE CH3 0 
11 H 
Physostigmine (eserine) 
O 
0-C W'ý 
H3 
6H3CH3 
(b) MONOQUATERNARY AMINE 
0F OH 
Edrophonium 
C2H5-N(CH3)2 
'Tensilon' 
0 CH3 
11 / 
Neostigmine 
N 
CH3 
'Prostigmin' 
N(C 
0 CH3 
Pyridostigmine 11 
'Mestinon' 
O 
CH3 
fN 
CH3 
(c) BISQUATERNARY AMINE 
OC 
II 
OO (C 
Distigmin 
'Ubrettid' CH3 2 
ocý 
Demecarium O To-oý ýC Jj o 
'Rosmilen' fN(CHý3 2 
TABLE 1.1 
Representative "reversible" anti-ChE agents employed clinically. 
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neuromuscular blocking agent, decamethonium, is presumed to act 
at two adjacent cholinoreceptors. Another class of bis- 
quaternary compounds is represented by the dioxamide, ambenenium, 
used in the treatment of myasthenia gravis. In addition to its 
potent anti-ChE activity, this drug has a variety of actions at 
both the prejunctional and postjunctional membranes of the 
skeletal muscle motor end-plate (Karczmar 1967). The other 
bis-quaternary amine, distigmine (Ubretid), is a long acting 
reversible anti-ChE agent with a much longer duration of 
action than neostigmine and pyridostigmine. It is 2.7times 
more powerful in the invivo inhibition of non-specific ChE in 
the whole blood of the rat (Chan 1980). Clinically, it is used 
in the prevention and management of post-operative urinary 
retention, intestinal atony and paralytic ileus in surgical and 
gynaecological patients. Occasionally it is also used as an 
adjuvant in the treatment of myasthenia gravis (Chan 1980). 
PHARMACOLOGICAL AND TOXIC PROPERTIES OF ANTI-ChE AGENTS 
The pharmacologic effects of anti-ChE agents are due 
primarily to the fact that the acetylcholine (ACh) released 
in the course of normal physiological activity is not destroyed. 
The released ACh, therefore, accumulates in the body where it 
exerts both muscarinic and nicotinic actions. The effects of 
individual anti"ChE agents may be modified by their other 
properties; some anti-ChE agents have an ACh like action in their 
own right, while others may cause neuromuscular blockade. 
The effects of some compounds are complicated by the production 
in vivo of other toxic substances. Lipid soluble substances, 
such as organophosphorous derivatives, penetrate easily into the 
-16- 
central nervous system and their central effects are, therefore, 
more pronounced than those produced by anti-ChE agents of lower 
lipid solubility. Finally, some of the anti-ChE agents have 
additional actions which arise, neither from their relationship 
to ACh or ChE, nor to their metabolic transformation into toxic 
substances. While these possible sources of variation in 
pharmacological activity should be borne in mind, the major 
actions of all the anti-ChE can nevertheless be summarized by 
Table 1-2. All muscarinic effects of anti-ChE can be 
attenuated or abolished by atropine. The central stimulation 
effects are antagonized by atropine although, not as completely 
as the muscarinic effects at autonomic effector sites. 
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TABLE 1-2 
PHARMACOLOGIC AND TOXIC EFFECTS OF ANTI-ChE AGENTS 
SITES OF ACTION EFFECTS 
MUSCARINIC EFFECTS 
Smooth muscles Increased peristalsis, miosis, 
relaxed sphincters, brocho- 
constriction, vasodilation and 
cycloplegia. 
Cardiac muscles Bradycardia and vasodilatation, 
hypotension. 
Exocrine glands Lacrimation, salivation and 
sweating. 
NICOTINIC EFFECTS 
Skeletal muscles Generalised muscle twitching 
followed by muscle weakness, 
muscle cramps. 
Ganglia Stimulation and modification of 
muscarinic effects. 
CENTRAL EFFECTS 
General Restlessness, dizziness, tremor, 
insomnia, aphasia, disorientation, 
hallucination. 
Poisoning Coma, convulsions and death. 
* Not all ACNE agents penetrate into the central nervous system. 
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THE EFFECTS OF THE OUATERNARYANTI-ChE AGENTS ON NEUROMUSCULAR 
TRANSMISSION 
The quaternary ammonium anti-ChE drugs such as 
neostigmine, pyridostigmine and edrophonium are known to have a 
facilitatory action on neuromuscular transmission (Randall and 
Jampolski 1953). The increased tension developed in the muscle 
due to the anti-ChE agents is thought to result from the 
production of a series of repeated discharges in the muscle 
fibres in response to a single supramaximal nerve stimulation 
(Wescoe and Riker 1951). The precise mode of action of these 
drugs has not yet been fully established, but several mechanisms 
have been suggested. It was originally proposed that their 
facilitatory action was due to the inhibition of AChE at the 
end-plate resulting in the persistance of transmitter at the 
junctional region. Many authors still adhere to this original 
supposition (Hobbiger 1952; Smith, Cohen, Pelikan and Unna, 1954; 
Katz'and Thesleff 1957; Ferry and Marshal 1971; Whittaker 1975). 
However, in-recent years it has been questioned whether these. 
anti-ChE drugs produce facilitation of neuromuscular 
transmission only by the inhibition of AChE at the motor end- 
plate. The possibility that the facilitatory action of these 
drugs may be attributed to the depolarizing action of the 
quaternary ammonium group has been proposed on the basis of a 
direct stimulating action on mammalian skeletal muscle. 
For example, the inter-arterial injection of neostigmine into 
chronically denervated muscle, or into normally innervated muscle 
in which essentially all the AChE has been inactivated by a 
prior dose of DFP (Di-isopropylphosphorofluoridate), evokes an 
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immediate contraction, whereas physostigmine does not (Riker and 
Wescoe 1946). 
It has also been suggested that the anti-ChE compounds 
induce antidromic discharges. in the pre-synaptic nerve terminals 
which are then disseminated by local axon reflexes causing the 
additional release of transmitter (Riker, Roberts, Standert and 
Fujimort 1957; Werner and Kuperman 1963; Blaber and Christ 1967). 
Thus, the mode of action of these drugs may be due to one or a 
combination of any of these suggested mechanisms. 
THE USE OF ANTI-ChE DRUGS IN MYASTHENIA GRAVIS 
The major therapeutic uses of the quaternary ammonium anti-ChE 
drugs are in the stimulation of the smooth muscles of the 
intestinal tract and the urinary bladder, the reduction of high 
intra-ocular pressure in glaucoma, the reversal of drug induced 
neuromuscular blockade after surgical anaesthesia and the diagnosis 
and treatment of myasthenia gravis. Myasthenia gravis is 
characterised by weakness and rapid fatiguability of skeletal muscle. 
The close resemblance of myasthenia gravis to curare poisoning 
reported by Jolly in 1825, and the success with treatment of 
myasthenia gravis in the 1930's (Walker 1934,1935), have long 
indicated the involvement of a defect in neuromuscular 
transmission. The difficulty has been the exact location of 
this defect. There are three major hypotheses concerning the 
pathogenesis of this disease: Firstly, a presynaptic defect 
in the synthesis or release of ACh, resulting in the failure 
of an appropriate amount of ACh to reach the receptor sites 
of the sub-neural apparatus following rapid repetitive nerve 
stimulation. Secondly, a circulating competitive blocking 
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agent interfering with the normal interaction between ACh and 
the post-synaptic receptor. Finally, a deficiency in post- 
synaptic receptors or a generalised decrease in the sensitivity 
of the receptors to ACh in consequence of an auto-immune 
reaction towards the nicotinic receptors at the motor end- 
plate. 
The suggestion that myasthenia gravis may be due to 
impaired release of ACh from motor nerve endings (Desmedt 1959), 
resulted from the resemblance between the post-tetanic exhaustion 
of myasthenic muscle and of normal muscle treated with Hemi- 
cholinium which inhibits the synthesis of ACh. Elmquist, 
Hoffman, Kugelberg and Quastel (1964) found that miniature 
end-plate potentials in myasthenic patients were normal in 
frequency, but decreased in amplitude. They tentatively 
interpreted this observation as being due to a decrease in the 
amount of ACh released from the nerve terminal. However, 
this decreased amplitude might equally be due to a decreased 
number or the decreased sensitivity of a normal number of post- 
synaptic receptors. 
Reports have been made of the demonstration in the blood 
of myastbenic patients of a substance capable of producing 
neuromuscular block in experimental animals (Wilson and 
Stoner 1944). It has been shown that thymopoetin which is the 
thymic hormone, released and responsible for inducing the 
differentiation of T-cells, in thymic diseases, causes a 
neostigmine responsive neuromuscular block in mice which resembles 
that of myasthenia gravis. Such evidence would lend support to 
the empirically proven treatment in a high proportion of patients 
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with myasthenia gravis by early total thymectomy (Keynes 1954). 
The poor results of thymectomy in some cases have been 
attributed to residual or ectopic thymictissue (Harvey 1948), 
or to irreversible damage caused by long standing disease 
(Wolf 1966). 
Myasthenia gravis may also be due to an auto-immune response 
in which an antibody to the end-plate receptor protein is produced 
by the reticulo-endothelial system (Simpson 1960). This 
suggestion was supported by the finding of antibodies to the 
skeletal muscle which also react with the myo-epithelial cells 
of the thymus in the serum of 507. of patients with myasthenia 
gravis (Downes, Greenwood and Wray 1966). However, in patients 
with observable thymoma the incidence was almost 1007. (Oosterhuis, 
Van Der Geld and Feltkamp 1967). In addition, studies 
utilizing labelled a -bungarotoxin, a snake venom that 
irreversibly binds to ACh receptors has shown that the number of 
receptors at the motor end-plate is considerably reduced in 
myasthenia gravis (Farnborough, Drachman and Satymurti 1973). 
In myasthenia gravis" there is, therefore, evidence of 
immunological reactions to the ACh receptor protein which could 
reduce the number and possibly the sensitivity of the ACh 
receptors at the motor end-plate and thereby produce the 
pathological and pharmacological symptoms associated with this disease. 
Noestigmine, pyridostigmine and ambenonium are the standard 
anti-ChE drugs used in the symptomatic treatment of myasthenia 
gravis. All can increase the response of myasthenic muscle to 
repetitive nerve impulses, probably primarily by the 
preservation of endogenous. ACh and secondarily by their direct 
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cholinomimetic action. When the diagnosis of myasthenia 
gravis has been established, treatment can be instituted with 
any of these drugs, then change if optimal improvement in 
strength is not achieved initially or at any time subsequently. 
In the majority of patients, especially in those with 
predominantly bulbar involvement, best results can be obtained 
with pyridostigmine, which is available only in certain 
countries, as time-span tablets containing a total of 180mg 
of which 60mg is released immediately and 120mg over several 
hours. This preparation is of particular value in maintaining 
patients overnight. 
When the muscles of the extremities are most affected, 
ambenonium or neostigmine may be the drug of choice. Not 
infrequently better results can be obtained by alternating 
equivalent doses (See Table 1-3) of different anti-ChE or by 
combining fractional doses of two agents. 
TABLE 1-3 
APPROXIMATE DOSES OF COMMONLY USED ANTI-ChE 
DRUGS ORAL 
DOSE 
INTRAVENOUS 
DOSE 
INTRAMUSCULAR 
DOSE 
Neostigmine 
"Prostigmine" 15mg 0.5mg 1.0 - 1.5mg 
Pyridostigmine 
"Mestinon" 60mg 2.0mg 2.0mg 
Pyridostigmine 
"Time-span" 180mg - - 
Ambenonium 
"Mytelase" 5-7.5mg none none 
available available 
-23- 
Patients with generalised myasthenia gravis maintained on 
ambenonium often need supplementation with pyridostigmine 
45 - 60minutes before meals to facilitate mastication and 
deglutition. Parenteral administration of the standard anti- 
ChE agents is sometimes requested in desparately ill myasthenic 
patients who do not respond adequately to oral medication, 
the subcutaneous, intramuscular or intravenous route may be 
used. Atropine sulphate 0.4 - 0.6mg or more, intravenously 
should be given immediately if a severe reaction (choliner4iC 
crisis) ensues. 
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PHARMACOKINETICS 
INTRODUCTION 
The word pharmacokinetics was introduced by Dost in 1953 
to mean the application of kinetic studies to drugs and poisons 
(Greek Pharmakon). The term incorporates the kinetic aspects 
of in vivo absorption, distribution, metabolism and excretion 
of drugs, poisons and some endogenous substances. 
Pharmacokinetic studies use data obtained from concentration 
curves of drugs or their metabolites in biological fluids; this 
data is processed by means of mathematical equations. The 
relationship between pharmacological response and concentration 
of drugs or their metabolites in body fluids is also included 
within the scope of pharmacokinetics. 
The study of pharmacokinetics was originated over 40 years 
ago. Widmark (1922) dealt exhaustively with the pharmacokinetics 
of ethyl alcohol and his mathematical treatment is still used. 
Equations describing first-order processes for absorption and 
elimination were derived by Gehlen (1933) and Beccari (1938). 
Tarsten Teorell (1937 a, b) first developed the theory of 
compartments and this work laid the foundation for much of 
modern pharmacokinetics. Teorell assumed that the drug 
and/or its metabolites were equitably dispersed in one of 
several tissues of the body and that the drug in these tissues 
acted as kinetically homogenous. Such a tissue, which acts on 
isotropicfluid, is termed a compartment. Compartments are 
separated by barriers that inhibit free diffusion from one 
compartment to another. The barriers are kinetically definable 
-27- 
in that the rate of transport of drug (or metabolites) across 
the membrane between the compartments is a function of the 
amounts of drugs in these compartments. 
Progress in pharmacokinetics was initially slow, due to 
widespread criticism of the compartment theory. However, the 
ideasof Teorell were reborn in the work of Druckery and 
Kupfmuller (1949) and Dost (1953); both groups of workers 
utilized data obtained from blood. The use of data obtained 
from urine for pharmacokinetic analysis was extended by Wiegand 
and Taylor (1960). The compartment theory is now generally 
accepted and coupled with the development of more precise 
means of measuring the required experimental data pharmacokinetics 
has made dramatic advances in the last decade. 
CONCEPTS OF PHARMACOKINETIC MODELLING 
Wagner (1968) described reasons and advantages of 
pharmacokinetic modelling to interpret quantitatively the fate 
of a drug in the body. These are; to summarise observed data 
in terms of an equation or equations which may help to describe 
better the fate of a drug than a plasma concentration-time' 
profile of the drug; to increase understanding of the disposition 
process (absorption, distribution and elimination) involved, 
to be able to predict dosage regime for better quality of therapy, 
to compare several drugs with similar pharmacologic action for 
screening of new drugs, and to quantitatively relate biological 
activity with pharmacokinetic data for better control of drug 
action. 
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The advance of analytical techniques for the determination 
of drugs in biological fluids has allowed more accurate and precise 
analysis to describe the fate of drugs in the body. The term 
'compartment' should not be restricted to the well-known body 
fluid compartments or organs; a pharmacokinetic compartment is 
referred to as a hypothetical region in the body where the drug 
concentration is everywhere the same, and is not related to any 
particular anatomical compartment. But it is helpful to 
conceptualize the central pharmacokinetic compartment as 
consisting of such physiological units as the extracellular 
space and well-perfused organs (e. g., kidney and liver), and the 
peripheral compartment as consisting of poorly perfused organs 
and tissues (e. g., muscle or fat). Drug elimination (via renal, 
biliary and other routes of excretion and metabolism) is usually 
assumed to occur from the central compartments. 
It is assumed that the processes of absorption, 
distribution and elimination associated with each model can be 
described by first-order rate kinetics, where the rate of transfer 
of a given drug is proportional to the amount or concentration 
of the drug. Kinetic linearity was defined by Kruger-Thiemer 
(1968) as direct proportionality of transfer rates or 
concentration of differences of drugs. Many authors have 
derived equations to interpret data for linear pharmacokinetics 
(Benet and Turi 1977; Benet 1979; Thron 1974). 
A modern view of pharmacokinetics was emphasised by 
Wagner (1973) to include both linear and nonlinear systems. 
He reviewed over 160 examples of nonlinearities in 
pharmacokinetics. The cause of nonlinear pharmacokinetics is 
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due to a deviation from first-order rate kinetics. 
Nonlinearities can result from incomplete or abnormal drug 
absorption, in binding reactions to limited numbers of binding 
sites on plasma proteins or in tissues, in active transport 
processes with limited available carrier, in active tubular 
secretion and reabsorption in the kidney, in biliary excretion 
of drugs and their metabolites, and in enzymatic transformations 
obeying Michaelis-Menten kinetics which is dose dependent kinetics. 
Enzyme stimulation and inhibition may also cause nonlinearities. 
It is important to recognize nonlinearity deriving a pharmaco- 
kinetic model. Sometimes this deviation becomes less obvious 
if data are obtained from carefully designed experiments. 
Beckett, Salmon and Mitchard (1969), by maintaining an acidic 
urinary PH, demonstrated that the urinary excretion rate of 
amphetamine follows first-order kinetics, whilst formerly 
it was not possible to investigate the pharmacokinetics of 
amphetamine in man (Beckett and Rowland 1964). Although 
Wagner (1973) emphasised that most drugs show nonlinear 
pharmacokinetics charactierstics, the concept of linear pharmaco- 
kinetic theory can be based just as easily on the simple 
assumption of linearity, with no assumptions regarding 
pharmacokinetic details. A theory resting on this foundation 
is much less vulnerable than one based on a possible erroneous 
specific pharmacokinetic model. 
PHARMACOKINETIC MODELS. 
After a drug reaches the general circulation, it can 
undergo a variety of processes, diffusion and binding in 
extravascular fluids and tissues, metabolism, nonenzymatic 
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chemical reaction and excretion. Excretion may take place in 
several pathways, the most common one is through the kidneys 
and bile, other routes include the skin, lungs and gastrointestinal 
tract. An enterohepatic cycle may develop where biliary 
excretion and intestinal absorption continue until most of the 
drug is eliminated through other pathways. 
ONE COMPARTMENT MODEL 
Often the rate of concentration changes for a drug in 
blood, plasma, or serum can be described as a single first- 
order process after an initial rapid distributive phase (Fig 2.1). 
That is, after a rapid intravenous injection the logarithm of the 
plasma drug concentration decreases linearly as a function of 
time as shown in Figure 2.2. 
The Figure 2.1 illustrates this one compartment rate 
constant for elimination K of the drug quantity in the body X, 
is equal to the sum of the apparent rate constant for 
metabolism, Km and excretion Ke: - 
K-KK+Ke Equation (1) 
For most drugs the rate of elimination is proportional to the 
amount of drug in the body (X) at any time t: 
dX -KX Equation (2) 
The negative sign indicates that drug is being lost from the 
body. Integration of equation (2) produces: 
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FIG 2.1 
A typical one compartment model of a drug, where Ka, Ke, Km are 
absorbtion, excretion and metabolism rate constants respectively 
X is amount of drug in the body. 
Ka 
dose 
IV 
ei 
4 
a 
00 
time (hrs) 
FIG 2.2 
Log C versus time, drug plasma level elimination according to 
Model 1. 
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X Xoe-Kt Equation (3) 
Where X0 is the amount injected (i. e., dose) and 
e represents the base of the natural logarithm. Taking the 
natural logarithm of both sides of equation (3) and then 
converting to common logarithms (base 10, log), gives: 
Log X log R Kt 
o 2.303 
Equation (4) 
The body is obviously not homogenous even if plasma 
concentration and urinary excretion data can be described by 
representing the body as a one-compartment model. Drug 
concentration in the liver, kidneys, heart, muscle, fat and 
other tissues will usually differ from one another as well 
as from the concentration in the plasma. If the relative 
binding of a drug to compartments of these tissues and fluids is 
essentially independent of a drug concentration, then the ratio 
of drug concentration in the various tissues and fluids is 
constant. Consequently, there will exist a constant 
relationship between drug concentration in the plasma, C, and 
the amount of drug in the body: 
Xa VdC Equation (5) 
The proportionality constant Vd in this equation happens to 
have the units of volume and is known as the apparent volume 
of distribution. Despite its name, this constant usually 
has no direct physiologic meaning and does not refer a real 
volume. 
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The relationship between plasma concentration and the 
amount of drug in the body, as expressed by equation (5). 
enables the conversion of equation (4) from an amount-time to 
concentration-time relationship which can be expressed as 
logC"- logC _ 
Kt 
o 2.303 
Equation (6) 
Where C0 is the plasma drug concentration immediately after 
injection (t - o). Equation (6) shows that a plot of log C 
versus t will be linear under the stated conditions (Fig 2.2). 
Co may be obtained by extrapolation of the log C versus t 
plot to time zero. This intercept, Co, may be used in the 
calculation of the apparent volume of distribution. 
Since X0 equals the amount of drug injected intravenously 
i. e., the intravenous (I. V. ) dose, Vd may be estimated from 
the relationship: 
VdsI. 
V= 
0 
Equation (7) 
It follows from equation (6), that if plasma concentrations 
are plotted on a logarithimic scale against time, a straight 
line should result. The slope of such a plot is 
-K/2.303 and related to the biological half-life (tb) of drug 
through equation (8) 
K-0.693 Equation (8) t/ 
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Nelson and O'Reilly (1960) derived an equation which 
describes the amount of unchanged drug excreted at any time 
during the post-absorptive phase after distribution equilibrium 
has been established, equation (9) 
U-U O* (1 - e-Kt) 
KXo (1 - e-Kt ý Equation (9) 
The terms U and U °O represent the amount of unchanged drug 
excreted up to time t and infinite time, respectively. 
Differentiating equation (9) and taking logarithms yield 
equation (10) 
log ät - log KUO° - 
Kt Equation (10) 
log KeX - 
Kt 
0 2.303 
It follows from equation (10), that if the logarithm of the 
rate of excretion is plotted against time, a straight line 
should result. The slope of this line will also be 
-K/2.303. Equation (8) can be used for the determination of 
the biological half-life of the drug. 
Data obtained from urine has been processed in the above 
manner in order to obtain K and the t for drugs. such as 
sulphrnamides (Swintosky 1957; Nelson and Schaldemes 1959; 
Nelson and O'Reilly 1960); digitoxin (Swintosky 1957); 
amphetamines (Chapman et al., 1959; Beckett and Rowland 1965b) 
paracetamol (Cummings et al., 1967) and chloropropamide 
(Taylor 1972). 
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Urine data can also be employed to estimate the individual 
rate constants which are included in the term Kel. The 
excretion rate constant (K e) can 
be calculated from 
equation (11): 
Re U°° 
RX 
0 
Equation (11) 
Where X0 is the amount of drug absorbed. If the drug is 
completely absorbed X0 will be equivalent to the dose of drug 
administered. Substituting the calculated value of Ke in 
equation (1), m may be determined. The later value may be 
a hybrid rate constant, since it can combine the rate 
constants of further biotransformations, as indicated in 
equation (12). 
Rý _ (Rml + Kim2 + Km3 .... ICS ) Equation (12) 
Plots of log rate of excretion or plasma level against time 
do not always yield a straight line. The influence of slow 
distribution of the drug throughout the body on this relationship 
has been discussed by Nelson (1964), who also observed that 
if the results of several individuals are averaged a deviation 
from the straight line relationship occurs. Plasma protein 
binding of drugs also has an influence on this curve (Kruger- 
Thimer 1966c; Kruger-Thimer et al., 1969; Diller 1964 and 
Martin 1965a, b; and Wagner and Northam 1967) have discussed the 
introduction of a second body compartment to explain these 
deviations. 
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In this simplest form of the one compartment model, 
after a rapid intravenous (I. V. ) injection, the drug is placed 
into the single compartment and consequently there will be no 
absorption phenomena (see Fig 1.1). Alternatively, an I. V. 
infusion can be employed and the pharmacokinetic parameters 
can be assessed from post-infusion blood curves. 
TWO-COMPARTMENT MODEL 
There is often an initial rapid fall of the drug 
concentration in the blood (and urine) when the drug is 
administered intravenously (I. V. ), and then its first-order rate of 
elimination is established (Fig 2.4). Garrett (1964) and 
Garrett and Alway (1963) have shown that this type of data 
is best analysed by a two-compartment open model. This model 
was first related to drug kinetics by Teorell (1937a, b). It 
presumes that a drug administered I. V. rapidly equilibrates 
between two-compartments, a central compartment and a peripheral 
compartment (Fig 2.3). 
Usually elimination (metabolism and excretion) is considered 
to occur at a rate proportional to the drug concentration in the 
plasma. However, metabolism could occur in the tissues and 
this possibility was investigated for acetylalycylic acid 
by Rowland et al., (1970). 
/ 
If the model shown in Fig 2.3 is assumed to be correct, 
then there is a rapid initial drop in blood concentration of 
drug (Fig 2.4), until a pseudo-steady state is established 
between the drug in the central (or blood) compartment. Changes 
in the concentration in the blood can then be related to changes 
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FIG 2.3 
Schematic representation of a two-compartment system consisting 
of a central compartment and a peripheral (tissue) compartment. 
_Iv 
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where Xc and Xp are the amount of drug in the central and 
peripheral compartments respectively, K21 and K12 are the 
apparent first-order intercompartmental rate constants and 
K10 is the apparent first-order elimination rate constant 
from the central compartment. 
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FIG 2.4 
A semilog plot of the plasma level of a drug which obeys the 
kinetics of a two-compartment model of I. V. administration. 
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in the concentration of the tissue compartment through the 
equilibrium or partition constant (K21/K12). 
DRUG LEVEL IN THE CENTRAL COMPARTMENT 
Following rapid I. V. injection of a drug that distributes 
in the body according to a two-compartment model with 
elimination occuring from the central compartment, the rate of 
change in the amount of drug in the central compartment Xc 
can be described by the following differential equation: 
dXc R dt -21 Xp K12 
Xc - K10 Rc Equation (13) 
Where X, is the amount of drug in the peripheral compartment, 
K21 and K12 are the apparent first-order intercompartmental 
distribution rate constants, and K10 is the apparent first- 
order elimination rate constant from the central compartment 
(see Fig 2.3). Taking the Laplace transform of equation (13) 
yields equation (14) and after partial fraction analysis of 
equations (14) and (15), the amount of drug in the central 
compartment Xc is given by equation (16): 
« +I9 * K12 + K21 + K10 
«. 9 - K21K12 
Xc Xo 
(a -K 21) -. rt e 
a-, 9 
Xo (K21 - ft > 
a-, 9 
Equation (14) 
Equation (15) 
e- 
Pt 
Equation (16) 
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Where oe and e are complex constants which simply serve to 
replace other constants as in equations (14) and (15); X0 is 
the intravenous dose. 
Although the central compartment is obviously not 
homogeneous by assuming that the ratio of drug 
concentrations in the various tissues and fluids of the 
central compartment is constant (i. e., there is a very rapid 
distribution between the plasma and fluids and tissues of the 
central compartment), a linear relationship exists between the 
drug concentration in plasma C and the amount of drug 
in central compartment, that is: 
XV. C 
cc 
Equation (17) 
Where Vc is the apparent volume of central compartment. This 
relationship enables the conversion of equation (16) from an 
amount-time to a concentration-time equation, which can be 
expressed as: 
C 
Ro( Of-K21) 
-art 
Ro(K21-B )e-, 
Vt -e+ 
vc (a- ß) v (a-ft) Equation (18) 
Or 
C Ae G(t + Be-. 0 t Equation (19) 
where 
A-x0(a-K1) 
va-e 
Equation (20) 
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and 
x0 (K21 -8) Equation (21) 
A plot of the logarithm of drug plasma concentration versus time 
according to equation (19) will yield a bioexponential curve 
(Fig 2.4). The constant oc is by definition larger than 89 
and therefore at some time the term Ae 
at 
will approach zero 
while Be 'Bt will still have a finite value. Equation (19) 
will then reduce to: 
C- Be . -Bt Equation (22) 
which in common logarithms is: 
Equation (23) log C- log B-2.303 
Hence, an estimate of ý9 can be obtained from the slope - 
ß/2.303 of the terminal exponential phase, and biological tk 
can be determined employing the following relationship: 
0.693 Equation (24) 
The zero-time intercept obtained by extrapolation of the 
terminal, linear phase to t-o is B. Application of 'the method 
of residuals' yields a second linear segment with a slope equal 
to - «/2.303 and a zero-time intercept A. 
The constants A. B. a and ß may be obtained graphically as 
shown in Fig 2.4, or with the aid of a digital computer. 
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The first approach is to fit the entire plasma level-time curve 
by means of a digital computer program which provides a nonlinear 
regression analysis of the curve. Once these experimental 
constants are obtained, the pharmacokinetic parameters Vc, 
K12, K21 and K10 can be generated by considering the following 
relationship. 
At time tao, equation (19) becomes 
C -A+ B 0 
Equation (25) 
Where C0 is the zero-time plasma concentration, substituting the 
values of A and B from equation (20) and equation (21), 
respectively into equation (25), and then simplify it yields: 
C= Xo 
0 Vc 
According to equation (25)t yields: 
Vc = 
Xo 
ÄB 
Where X0 is intravenous dose. 
Equation (26) 
Equation (27) 
Rearrangement of equation (27) and substitution A+B 
in equation (21) yields: 
(A+a)(K21-ý) 
Ba- Equation (28) 
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K21 =A+B *f Equation (29) 
A+B 
K10 =K Äý+ 
Bä) Equation (30) 
21 
Determination of these rate constants permits an assessment of 
the relative contribution of distribution and elimination 
processes to the drug concentration versus time profile of a 
drug. It may also aid in elucidating the mechanism of drug 
interactions and of effects of disease, age, genetic influence, 
etc., on drug disposition. 
One useful additional equation is the equation for the 
total volume of distribution of drug in the body: 
V K 
vd. 
_ Equation (31) 
Where Vd can be defined as the apparent volume of distribution 
of drug in the body (Gibaldi 1975). The parameter Vd will 
relate the amount of drug in the body to the plasma 
concentration at any time during the postdistributive phase, 
that is 
Vd x0 Equation (32) 
ßf Cdt 
which is a useful relationship for estimating Vd 
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DRUG LEVELS IN THE TISSUE (PERIPHERAL COMPARTMENT) 
The differential equation describing the rate of change 
in the amount of drug in the peripheral compartment is: 
dt 
- K12Xc - K21XP Equation (33) 
Where Xc and Xp are the amount of drug in the central and 
peripheral compartment respectively. After the Laplace 
transformation and partial fraction analysis of equation (33) 
yield equation (34) 
Xs 
K12Xo 
e- at 
K]= 
-pt 
p+et Equation 
(34) 
or 
X 
pa Xs 
2X (e- Rt T e- at) Equation (35) 
Equation 35 describes the time-course of the amount of drug 
in the peripheral compartment following intravenous administration. 
It is obvious from equation (35) that after a sufficiently long 
d 
period of time the term e- 
t 
approaches zero and equation (35) 
reduces to 
X 
R1= 
eSgt p a-/4 Equation 
(36) 
Hence, the slope of the terminal exponential phase equals to 
-fß/2.303. Therefore, in the postdistributive phase. plasma 
and peripheral compartment levels decline in parallel. 
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Equation (36) may be useful in determining the relationship 
between pharmacologic effect and tissue levels of a drug. 
It must be kept in mind, however, that such relationships are 
only approximations. The hypothetical tissue levels may not 
accurately reflect the concentration of drug at the site of 
action, even though the site of action may be a part of the 
peripheral compartment (Gibaldi 1975). 
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SOME APPLICATION OF PHARMACOKINETIC PARAMETERS. 
(a) PLASMA OR BLOOD LEVELS OF DRUG AND PLASMA t 
Measuring plasma or blood concentrations of drugs and 
deducing the plasma half lives, t, from such data has often 
been used to monitor drug therapy. Plasma level determination 
is unnecessary if the patient responds satisfactorily to a 
carefully chosen dosage schedule, but can clarify the situation 
when the desired therapeutic effect is not achieved or when toxic 
effects are suspected or when the patient has not taken the 
drug. However the interpretation of drug plasma or blood 
levels becomes difficult when there is an intersubject variation 
in the plasma or blood profile of the drug. Factors which are 
responsible for their inter-individual variations have been 
discussed by Vesell (1973). There are genetic variations and 
variation in the absorption, distribution and elimination of the 
drug among individuals which may be due to environment or- 
disease states. When all these factors are operating in 
severely ill patients, drug plasma or blood are difficult to 
interpret. Therefore, utilisation of plasma or blood 
concentration of drug or its plasma tý as a therapeutic guide 
alone may be limited (Perrier and Gibaldi, 1974). 
(b) THE APPLICATION OF AREA UNDER PLASMA OR BLOOD CONCENTRATION 
TIME CURVE (AUC) OF DRUGS 
Frequently, the technique of area analyais has been 
applied to assess the absorption and bioavailability of a 
drug. This is because the area under a blood level curve is 
proportional to the drug available from a dose (Wagner and 
Nelson, 1963; 1964; Loo. and Riegelman, 1968). However, it 
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is observed that there is a reduction in the AUC following oral 
drug administration as compared with that obtained after intravenous 
drug administration. This observation led to the assumption 
that orally administered drugs are either incompletely 
absorbed or metabolised in the gastro-intestinal tract. 
Subsequently, it is demonstrated that there is also a 
comparable reduction in the AUC after drug infusion via the 
portal vein. 
The total AUC of a drug can be easily calculated using 
Equation (37), which results from integration of equation (19): 
AUC cc +3 Equation (37) 
From equations(27)9 (30), and (37) Equation (38) can be 
obtained, which shows that AUC is directly related to the dose 
X0 and inversely to the elimination constant K10 and the 
volume of central compartment Vc. 
x 
AUC aO V 
cK10 
Equation (38) 
The AUC of a drug can also be determined according to 
equation (39): 
0o X 
AUC Xcdt =F(2) Equation (39) 
fo 
Hence, AUC is dependent upon the elimination rate constant, K. 
the volume of distribution V and the total quantity of available 
drug FXo. For a drug where the total orally administered dose 
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is absorbed, F=1, in a one compartment model. Similarly, 
the AUC is identical to that for the two compartment system 
except for the different definitions of distributive volume 
(K =, 9 and V= VB). Wagner (1967a) applied equation (40) 
to twelve separate studies with tetracycline and novobiocin 
F 
0.693V s Xo 
Ut Equation (40) 
/ 
combinations from 167 sets of serum tetracycline curves. Both 
children and adults were used in the studies. Similar relative 
tetracycline availability were evident from the average area/ 
dose times half-life ratios, which ranged from 1.09 to 1.23. 
Absolute availabilities can easily be assessed by a comparison 
of areas with the use of equation (4%), where the AUC per unit 
dose by any route of administration is expressed as a percent 
of the intravenous AUC per unit dose. The total quantities of 
intact drug excreted after any administrative route can also be 
compared to the intravenous data. 
Percent of absolute availability - 
(AUC) 
oral x 
Dosel. V. x 
100 
Equation (41) 
AUC I. V. x 
Dose 
oral 
Obviously, the percentage of absorption can only be obtained 
with equation (41) if no significant metabolism occurs before 
the drug reaches the general circulation. This was the case 
with the compounds studied by Dost (1963) and Gladtke (1964, 
1968). However, with oral administration, if the drug is 
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metabolized prior to, or during absorption, or during the 
'first pass' through the portal system, then the oral AUC will 
be less than that obtained after intravenous administration, 
even if absorption is completed. This was discussed by Harris 
and Riegelman (1969) with reference to a rapidly metabolized 
drug, asprin, using data obtained in dog experiments after oral 
dosage, vena -- cava and hepatic portal vein infusion. 
Gibaldi et al. (1971) described such observation as the 
'first-pass' effect, which indicates that drugs are exposed 
to metabolism in the liver before reaching the bloodstream 
after oral administration. 
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THE AIMS OF THE THESIS 
Clinical laboratories are in need of a reliable procedure 
to analyze quaternary ammonium drugs because this class of 
compound includes the neurotransmitter acetylcholine as well 
as the anticholinesteras', neostigmine and pyridostigmine, which 
are important in the diagnosis and management of myasthenia 
gravis. Individual differences in the dosage requirement of the 
drugs are commonly attributed to varying severity in the course 
of disease. The role of inter-individual differences in drug 
metabolism and excretion is a matter of conjecture since 
analytical methods that can be applied to the routine 
measurement of pyridostigmine and neostigmine concentrations 
in man have not been developed. 
The aims of the experimental work are to develop some 
sensitive and selective analytical methods to measure the 
concentration of the drug and their metabolites and also to 
investigate the pharmacokinetics of pyridostigmine and 
neostigmine after IV and IM and oral administration. It is 
hoped that the clinical findings will help to elucidate further 
the mechanisms of action of these drugs, permit a more 
systematic and controlled investigation of a similar nature and 
ultimately, help to identify the contributing factors in the 
difficult management of patients under going anticholinesterase 
therapy. 
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A REVIEW ON ANALYTICAL TECHNIQUES AVAILABLE FOR DISPOSITION 
STUDIES OF ANTI-ChE DRUGS 
Early techniques for the determination of quaternary 
Anti-ChE drugs and their metabolites in body fluids were based 
on spectrophotometry. After ion-pair extraction of the 
compounds into organic solvents, the ion-pair is subsequently 
dissociated with dilute hydrochloric acid and the quaternary 
amines can then be assayed by standard spectrophotometric 
techniques. These methods have been applied to the measurement 
of pyridostigmine in plasma (Coper, et al., 1974). The 
quaternary amine was extracted as an iodide complex into 
dichloromethane and its absorption was measured at various 
wave lengths. The limit of sensitivity of this assay 
procedure is 0.1 - 0.2 pg/ml, and interference by other drugs 
and endogeneous substance may occur. Kornfeld, et al. (1970) 
and Somani et al. (1972) have had little success with this 
procedure which does'not appear to separate pyridostigmine from 
its main metabolites; apparently, the major metabolite, 
3-hydroxy-N-methylpyridinium, gives maxima at 250,288 and 
320nm (Somani et al. 9 1972). A method for the estimation of 
neostigmine and pyridostigmine in urine was described using ion 
exchange treatment and colorimetric estimation of the blue 
complex produced when either of the drugs was complexed with 
bromophenol blue (Nowell et al., 1962). However, the procedure 
suffers from lack of sensitivity (lowest limit for detection 
is 2 to 3 pg/ml) and selectivity as the assay could not be 
used to distinguish between. neostigmine and pyridostigmine. 
0 
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- Radioisotopic techniques have been used to study the 
disposition of edrophonium in the rat using (14C)-edrophonium 
(Back and Calvey 1974). The disposition and metabolism of 
neostigmine in the hen and rat were studied using 
14C-labelled 
neostigmine (Roberts et al., 1965). Similarly, metabolism 
studies of pyridostigmine in rat (Birkt Y et al., 1966) and in 
man (Kornfeld et al., 1970) were carried out using 
14C-labelled 
pyridostigmine. These investigations are expensive and involve 
the administration of large doses of radioactivity and are not 
suitable for human studies. Radioisotopic techniques are 
often non-specific and cannot distinguish the parent drug from 
its metabolites. Electrophoretic and chromatographic 
techniques are often involved in the isolation and separation 
of parent drugs and metabolites when radioisotopes of the 
parent drugs are used. 
Enzymatic procedures have been used to assay reversible 
eta,, 
anti-ChE agents, such as edrophbnium, in plasma (Barber 1976). 
These methods have been used to study the correlation between 
the plasma concentration of the drug and pharmacological effects 
(Calvey et al., 1976). Although these assay procedures are 
sensitive, they are time-consuming and exacting and can only be 
used for truly reversible anti-ChE agents. 
Analyses based on gas-liquid chromatographic (GLC) 
techniques have been used for the quantification of some 
quaternary amines. For instance, acetylcholine was 
demethylated into dimethyl-aminoacetate by N-demethylation using 
benzenethiolate in butanone solution (Jenden at al., 1968); the 
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subsequent dequaternized dimethylaminoacetate was assayed by a 
GLC procedure. We have had limited success with this 
procedure for measuring neostigmine and pyridostigmine. 
Apparently the methylation of the quaternary nitrogen by 
benzenthiolate would also cause the hydrolysis of the 
carbonate ester and we did not obtain reproducible demethylation 
(Chan 1980). 
Methods based on thermal dequaternization have been 
reported for a number of quaternary compounds; including acetylcholine, 
acetyl-/-methyl choline, butyrylcholine and choline (Szilagyi, 
1968 and Schmidt 1975), thiazinolnium (Jonkman et al., 1975), 
neostigmine and pyridostigmine (Vidie, 1972; Chohan 1976). 
Vicie(1972) and Chohan (1976) in their methods used the 
methyliodide (part of the dequaternarnized products, see 
Chan 1980) as a measure of the quaternary amines in the plasma. 
However, this procedure suffers from lack of selectivity as 
other quaternary compounds may also be ion-pair extracted and 
similarly assayed. 
Recently, Chan et al. (1976) developed a sensitive and 
selective prowiedure based on GLC analysis, for the 
determination of nostigmine and pyridostigmine in human plasma. 
The procedure involved preliminary ion-pair extraction of the 
drugs using potassium iodine-glycine buffer, into dichloro- 
methane, followed by concentration and analysis of the ion-pair 
complex using GLC system fitted with a nitrogen-sensitive 
detector. Using peak area ratio techniques, pyridostigmine 
bromide was used as the internal marker for the determination 
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of neostigmine in plasma; neostigmine bromide was used as the 
internal standard for the quantitation of pyridostigmine. 
The method depends on the dequaternization of the quaternary 
nitrogen to form the tertiary analogue which is resolved by 
the GLC system. Chan et al. (1976) reported that gas 
chromatography-mass spectrometry (GC-MS) of a plasma extract 
containing neostigmine and pyridostigmine as iodide complex 
gave a one compound whose mass spectrum showed a molecular ion 
at n/e 166, and second compound with a molecular ion at m/e 208, 
corresponding to pyridostigmine and neostigmine bromide or the 
appropriate tertiary analogues of these drugs. Apparently, 
both Anti-ChE drugs, either as the bromide salt or as the iodide 
complex, were thermally demethylated to their corresponding 
tertiary analogues which were then resolved by the GLC 
system. Other authors have used similar methods to measure 
quaternary amines in plasma. The plasma and urine level of 
thiazinamium methylsulphate, an anticholinergic agent for 
treatment of bronchial asthma, was determined by a similar ion 
pair extraction and GLC procedure (Jonkman et al., 1975). 
Acetylcholine and its related analogues have been measured by an 
assay based on pyrolysis gas chromatography and pyrolytic 
products of these compounds are the corresponding 2-dimethyl- 
amine esters and methyl halides (Szilagyi, 1968; Schmidt, 1975). 
Aquilonius at al., (1979) reported an identical extraction 
procedure using deuterated d6- neostigmine as the internal 
standard and mass spectrometer as the detector for the 
determination of neostigmine in plasma. The limit of 
quantifation of this method. was about lng/ml, but the use of 
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GC-MS system is not always available in every laboratory due to 
the high cost of such a system. 
Electron capture gas chromatography method for determination 
of quaternary ammonium compounds has been reported by Pohlman 
and Cohan (1977). The principle of this analytical method is 
to isolate the quaternary ammonium compound as its iodide from 
biological fluids. The iodide extract is then thermally 
degraded to release methyl iodide upon its injection onto the 
chromatographic column and measured by the electron capture 
detector. This method has a few potential problems, including 
choline which is found in serum may also be demethylated at the 
temperature employed (Pohlman and Cohan 1977). Although these 
assay procedures are sensitive, they are time-consuming (over 
48 hours) and non-specific. 
High performance liquid chromatography technique has been 
reported for the quantitation of pyridostigmine in plasma by 
Yakatan and Tien (1979). Perchlorate was used as the 
canter ion in the extraction of pyridostigmine and measured at 
a wave length of 269nm using a UV detector. The limit of 
sensitivity of this assay procedure is 20ng/ml by utilizing 
1 ml plasma. Mean recovery from plasma was 63.97. (Yakatan 
and Tien 1979). 
RATIONAL FOR MONITORING PLASMA LEVEL OF ANTI-ChE DRUGS 
The influence of plasma concentrations of a drug by 
pharmacokinetic processes such as disposition and elimination, 
is often considered to be responsible to a greater extent for 
the variation in individual response to the drug than are the 
-58- 
differences in target organ sensitivity among individuals 
(Smith et al., 1973). Thus, the monitoring of plasma levels of 
drugs in pharmacotherapy may be of adverse side effects or 
reactions due to the drug or combination of drugs (Mucklow 
1973) and provide more efficient pharmacotherapy. 
At present, the regulation of the oral anti-ChE drugs for 
patients with myasthenia gravis is empirical, depending on the 
patients' subjective responses and on patients co-operation when 
testing motor strength. Edrophonium has been used as an* 
adjunct in regulation drug dosage (Osserman et al., 1966), but 
results are difficult to interpret and may not be helpful to the 
physician in deciding whether medication is necessary when the 
patient complains of motor weakness, dyspnea or diplopia. 
However, if a relationship between the plasma level of these anti- 
ChE drugs and clinical responses of the myasthenic patient 
could be demonstrated, it would be possible to regulate the dosage 
regimen by measurement of the plasma concentration of the drug 
to determine if the patient with an unsatisfactory clinical 
response to the anti-ChE drug treatment requires more 
medication or is manifesting symptoms of cholinergic crisis, due 
to drug toxicity from over medication. 
Recently, Chan and Calvey (1977) demonstrated that the 
plasma concentration of pyridostigmine was invariably positively 
correlated with the improvement in neuromuscular transmission 
in patients with typical electromyographic decrement in the 
adductor pollices. The plasma concentration to normal varied 
over a 5-fold range (27.8 - 125.7 ng/ml), reflecting the variable 
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severity of the disease. In a patient with purely ocular symptoms, 
there was a significant correlation between the plasma concent- 
ration of the drug and diameter of palpebral fissure. A 
separate study on the plasma level of pyridostigmine in 
myasthenic patients has shown considerable intersubject 
variation in the bio-availability of the quaternary amine 
(Calvey and Chan 1977); the six patients on an oral pyridostig- 
mine bromide were stablized on widely different doses of the 
drug (60 - 660mg/day). Therefore, the role of individual 
differences in drug disposition may no longer be a matter of 
conjecture and the monitoring of plasma levels of anti-ChE 
drugs should be of particular value in the clinical assessment 
of patients with myasthenia gravis. A method to calculate the 
optimal daily doses of pyridostigmine in individual myasthenic 
patients is described by Chan and Calvey (1977). For instance, 
the optimum plasma level of the drug for each myasthenic 
patient can be defined by relating the plasma concentration of 
pyridostigmine to determine the volume of distribution in the 
affected muscle groups. Subsequently, a test dose of oral and 
intravenous pyridostigmine could be used to determine the 
volume of distribution, the elimination half-life and the 
fraction of the dose of the drug required to maintain the 
steady-state plasma level can be calculated for each myasthenic 
patient, according to the following equation: - 
required steady-state volume of 
plasma concentration X distribution 
Dose U&/ml 
(ml/Kg) 
mg/Kg/24hr 
fraction of dose X half-life 
absorbed (min) 
-60- 
The pharmacokinetics of neostigmine after intravenous 
administration to surgical patients during the reversal of 
neuromuscular block have recently been investigated (Aquilonius 
1979; Smith 1973). We have done similar IV studies for 
pyridostigmine (see chapter 4). It is possible to utilize 
these pharmacokinetic parameters for the design of a dosage 
regimen as outlined in the above equation (Chan and Calvey 
1977). Such parameters may also help to select which one of the 
two anti-ChE drugs is better for treatment. Baker et al., (1978) 
have also studied the plasma clearance of neostigmine and 
pyridostigmine in conscious dogs by the use of a cross-over 
design. Results suggest that the longer duration of action 
of pyridostigmine is related to the differential clearance of 
the two quaternary amines from plasma, as the slow disposition 
half-life of pyridostigmine is approximately three times longer 
than that of neostigmine. 
CONCLUSION 
It is evident that previous methods for the study of the 
metabolism and disposition of anti-ChE drugs are not 
selective and sensitive. Over the last twenty years the most 
important progress observed in the research of fundamental biology 
has been in the technical means (Dreux 1979), such as electronic 
microscopy, gas-liquid chromatography, high performance liquid 
chromography, gas chromatography - mass spectroscopy, methods of 
structural determination for proteins and the use of 
immunological methods (enzymatic-multiple immunological 
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techniques and radio-immunoassay). With these techniques it 
is possible to measure minute quantities of drugs up to the 
molecular level 10-12g. The determination of anti-ChE drugs 
and their metabolites offers better assessment of anti-ChE 
therapy in myasthenia gravis and in the reversal of neuromuscular 
blockade after surgical operation. 
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PART TWO 
Development of methodology for the determination of 
neostigmine , pyridostigmine & their metabolites in 
human plasma & urine. 
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INTRODUCTION 
Sensitive and specific methods for the analysis of drugs 
in biological fluids are essential for pharmacokinetic studies, 
particularly when plasma concentrations of drugs which have a low 
post-absorption concentration or rapid elimination 
are studied after administrationof small doses. Assay 
methods reported for the determination of anti-ChE drugs; as mentioned 
earlier (Part One page 53 ) are difficult to use, or suffer from 
low sensitivity or lead to interference by other compounds. 
In this part, the latest development of the analytical 
methods and their application to the determination of anti-ChE 
drugs in human plasma and urine is described. These developed 
methods are based on the preliminary ion-pair extraction of 
neostigmine, or pyridostigmine and their major metabolites as well 
as appropriate internal standards into dichloromethane or 
dichloromethane: acetone(90: 10), followed by concentration and 
analysis of the ion-pair complex, using a GLC system, 
These developed procedures will be described in terms of the 
following section. 
Method 1 was used for the isolation and determination of 
neostigmine or pyridostigmine and their metabolites. To measure 
unchanged drugs, pyridostigmine bromide was used as an internal 
marker to measure neostigmine; and neostigmine bromide was the 
internal marker for the quantititation of pyridostigmine. 
To measure the metabolites of pyridostigmine and neostigmine 
in urine, one metabolite was used as the internal standard for 
the other and vice versa. 
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Method 2, developed for use in the simultaneous determination 
of the unchanged drugs using a common internal marker. 
METHOD 1. 
APPARATUS AND CONDITIONING 
A Perkin-Elmer model F17 gas chromatography all-glass 
system, fitted with a phosphorus-nitrogen detector and linked 
to a Perkin-Elmer chart paper Model 56 (Perkin-Elmer, 
Beaconsfield, U. K. ) and to an autolab minigrator (Spectra 
Physics) was used. 
For the determination of parent drugs, this instrument 
was operated with coiled glass columns (2m x 6.5am OD) silanized 
with Hexamethyldisilanize(HMDS) and packed with 107. OV-17 or 
37 OV-17 on chromosorb W-AW (100-120mesh); for the determination 
of metabolites, it was operated with 107. OV-17 on chromosorb W-AW 
(100-120 mesh). Gas flow-rates were: nitrogen (carrier), 30ml/min; 
hydrogen, 2m1/min; and air, 100ml/min. The temperatures were: 
3000C for the injector and the detector, and column temperature at 
C for parent drugs; and 190-200C for metabolites. 200 - 220° 
° 
All columns were conditioned at 200C below the maximum 
recommended temperature for the relevant stationary phases for 
24 hours. Each column was then silanized twice in situ with 
samples of HMDS (Phase Separation LTD, Great Britain) before 
use. 
Other apparatus used were: lOml capacity centrifuge tubes 
with well-fitting screw caps (Sovirel,, Leval lois-P erret, France); 
15 ml stoppered evaporating tubes with finely tapered bases 
(Beckett, 1966); ]Opl-S. G. E. microsyringe (Chromatography Services, 
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Wirral, Great Britain); Pipetman microsyringes (Anachem, 
Bedford U. K. ); thin layer chromatography (TLC), TLC plates 
covered with polyamide; 0.15mm thick (Schleicher and Schull, 
W. Germany); Automatic shaker (Recto, Denmark). 
MATERIALS 
The following materials were used. 
Acetone, dichloromethane, diethylether, ethanol and 
methanol, all of analar grade and freshly redistilled; Analar 
anhydrous sodium sulphate; ether-washed sodium hydroxide solution 
ON and 0.1N); O. 1M glycine buffer which is made up of the 
following: - 
Analar glycine 7.505g 
Analar sodium chloride 5.185g 
Distilled water to 1000ml 
Potassiuntodide-glycine buffer which is made up of: - 
Analar potassium iodide 12.8g 
O. lN Sodium hydroxide solution 4m1 
0.1M glycine buffer 6m1 
Potassium triiodide solution which consists of: - 
Iodine ig 
Potassium Iodide 2g 
Distilled water 20ml 
Neostigmine bromide (Koch-Light, Colnbrook, U. K. ); pyridostigmine 
bromide, U. S. P; 3-Hydroxy-pyridine and 3. d imethylaminophenol 
(Aldrich Chemical Company Limited, Gillingham, Dorset, U. K); 
3-hydroxy-N-methylpyridiniumbromide, 3-OHNMP (RocheWelwyn 
Garden, U. K); 3-hydroxyphenyltri-methylammonium bromide, 
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3-OHPTMA (Koch-Light, Colnbrook, U. K. ); 
14C-3-OHNMP 
and 
3H-3-OHNMP (The Radiochemical Centre, Amersham, U. K). 
TREATMENT OF GLASSWARES 
It was found that all glassware should be cleaned and 
silanized before use. Accordingly the following procedureýin 
order to increase the sensitivity of measurement of the drugs 
was used. A considerable quantity of the drug might be lost 
due to adsorption onto the walls of glassware. Evaporating 
tubes and screw capped centrifuge tubes were cleaned by soaking 
in a 2.5% solution of RBS (Chemical concentrates -RBS - Limited, 
London) in water overnight, then rinsed with methanol((Ommercial 
Grade) and hot tap water, followed by distilled water. The 
tubes were then dried at 105°C. After cooling at room 
temperature, all the tubes were silanized by rinsing with a 37. 
solution of HMDS in chloroform. They were then dried at 250°C 
overnight. Silanization of tubes should be repeated when 
necessary, at monthly intervals. 
DETERMINATION OF NEOSTIGMINE IN PLASMA 
Blood samples were obtained by venous puncture and 
collected in heparinized polythene tubes. After centrifugation 
(5000g for 10mins) the plasma samples (1.0 - 3. Oml) in a 10-ml 
glass centrifuge tube was made alkaline (pH 10-12) with 20pl 5N 
sodium hydroxide solution and the marker solution (60)jl; equivalent 
to 50ng base of pyridostigmine bromide in methanol was added. 
The alkaline solution was extracted with freshly redistilled diethyl 
ether (2 x 6m1) by shaking vigorously by hand for 2min. then centrifuged 
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at 3000g for 5min. to break the emulsion and the ethereal extracts 
were discarded. The remaining traces of ether were removed by 
purging nitrogen gas over the aqueous phase. Potassium iodide- 
glycine buffer (lml) was added to the ether-washed plasma and the 
resultant iodide-glycine drug complexes were extracted into 
freshly redistilled dichloromethane (2 x 6m1) using an automatic 
shaker. 
After centrifugation, the plasma layer was discarded and the 
bulked dichloromethane extracts were dried by shaking with a 
quantity of anhydrous sodium sulphate (Ca_ 2'9). The water-free 
extract was transferred carefully into an evaporating tube and 
evaporated to dryness by a gentle stream of nitrogen gas. 
Redistilled methanol (20pl) was added, using a Pipetman microsyringe, 
to redissolvethe dried extract by vortexing (5secs. ). A sample 
(2-5pl) of the methanolic solution was injected onto the gas 
chromatographic column with a 10p1 S. G. E. syringe. The 
concentration of neostigmine present in a sample was determined 
from the ratio of the integrated peak area for neostigmine to that 
for the internal marker. A calibration graph was prepared by 
adding known amounts of neostigmine bromide to 3m1 of drug-free 
plasma, covering the concentration range equivalent to 5.0 to 
100ng/ml neostigmine base (Fig 3.1). 
DETERMINATION OF PYRIDOSTIGMINE IN HUMAN PLASMA 
A procedure similar to the one described above was used for 
the determination of pyridostigmine in human plasma using 
neosticmine bromide as the internal marker. A calibration graph 
was prepared, by adding known amounts of pyridostigmine bromide to 
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3m1 of drug-free plasma, covering the concentration range 
equivalent to 5.0 to 100ng/ml pyridostigmine base. 
DETERMINATION OF ANTI-ChE AGENTS AND THEIR METABOLITES IN HUMAN 
URINE 
Neostigmine and its major metabolite 3-hydroxyphenyltrime- 
thyl-ammonium bromide (3-OHPTMA) as well as pyridostigmine and its 
major metabolite 3-hydroxy-N-methyl-pyridinium (3-OHNMP) could be 
separated by a TLC system consisting of a glass TLC plate 
(polyamide, 0.15mm thick)& a solvent system of methanol, 
strong ammonia solution &butan-2-one in the ratio, of 15: 20: 60. 
Visualization of the TLC spots was carried out using Dragendorff 
reagent (Clarke 1969) and under UV light (Chan and Black unpublished 
observation 1977). This system was used to identify the parent 
drugs and metabolites extracted from the urine samples using 
the procedure described in the scheme (Fig 3.1). 
Subsequently it was found that the TLC procedure was not sensitive 
for the quantification of the drugs. A GLC system was then 
developed using a 2m glass column packed with 107. OV-17 on 
chromasorb W-AW(100-120 mesh). 
Extracts from step 2 of the scheme (Fig 3.1) were analysed for 
the parent drug and the corresponding internal, standard and 
extracts from step 3 of the scheme were analysed for the 
metabolites using GLC system (107. OV-17 on chromosorb W-AW 
100-120mesh). To measure the metabolites, 3-OHPTMA., (a major 
neostigmine metabolite)was used as the internal standard for 
the quantification of 3-OHNMP(a major pyridostigmine metabolite) 
and 3-OHNMP was used as the internal standard for the determination 
of 3-OHPTMA. 
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RESULTS 
1. ION-PAIR EXTRACTION OF PARENT DRUGS AND METABOLITES 
It was demonstrated that the mean recoveries of neostigmine 
and pyridostigmine from plasma were 857. and 897. respectively, 
using potassium iodide-glycine buffer at pH10 (Chan et al., 1976). 
In the present method the recoveries were improved to 957, and 947. 
(at 60ng per ml level) respectively for neostigmine and 
pyridostigmine when all relevant glassware was silanized in the 
present modified procedure. This procedure invariably increased 
the sensitivity of detection at a low concentration 
level. 
Fig 3.2. shows that the ion-pair extraction of the neostigmine 
metabolite (3-OHPTMA) and the pyridostigmine metabolite 
(3-OHNMP) from the urine sample spiked with known concentrations of 
the parent drugs(neostigmine and pyridostigmine) and their 
corresponding metabolites was proved to be specific. There 
were no TLC spots corresponding to the metabolites from 
concentrate of the Step 2 (Fig 3.1) extraction in the general scheme 
nor were there TLC spots corresponding to the parent drugs 
extracted by Step 3 in the general scheme (Fig 3.1). 
The mean recoveries of 3-OHPTMA and 3-OHNMP, using 
potassium tri-iodide as counterions at pH4 were 807. at 
1.6nmol level using a previous procedure. Similar value of 
recoveries were obtained when radioactive samples were used 
(Wareing and Calvey, personal communication). 
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STEP 1 
1 or 3m1 urine, 500ng internal 
markers, 20jil 5NaOH (pHll), 2x 6m1 
diethyyether 
Discard diethyl ether to 
remove basic drug and 
lipid soluble substance. 
STEP 2 
Aqueous phase, lml KI glycine 
buffer (pHll), 2x 6m1 
dichloromethane. 
Evaporate organic extract 
to dryness, redisolve 
residue with methanol (20»l), 
GLC quantititation for parent 
drugs (2p1). 
STEP 3 
Aqueous phase, 60pl 3NHC1 
(pH4), 20p1 iodide solution, 
2x 6m1 dichloromethane, 
acetone (90: 10) 
Evaporate organic extract to 
dryness, redissolve residue 
with methanol (20»l), 
GLC quantitation for 
metabolites (2p1). 
FIG 3.1 
SCHEME FOR THE DETERMINATION OF NEOSTIGMINE, PYRIDOSTIGMINE 
AND THEIR METABOLITES IN URINE. 
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Rf values 
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PYR NEO POH NOH STEP 1 STEP 2 
FIG 3.2 
TLC of ion-pair extracts of pyridostigmine (PYR), 
neostigmine (NEO), 3-OHNMP(POH) and 3-OHPTMA (NOH) in urine 
containing spiked concentration of 5pg each. TLC plates: 
glassplate (polyamide, 0.15mm thick), solvent system: 
strong ammonia solution: butan-2-one: methanol (20: 60: 15). 
Developing spray: Dragendorff reagent, Temperature: 20 + 2°C. 
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TABLE 3.1 
PERFORMANCE OF GLC SYSTEMS (107. OV-17 ON CHROMOSORB W-AW, 
100 - 120 MESH)(a) 
RETENTION SYMETRTb) RESOLUTION 
TIME FACTOR BETWEEN 
(MIN) (0.95 - MARKER 
fib) 
COMPOUND IN METHANOL 1.05) i>1.0) 
3-OHPTMA bromide 6.3 1.0 3.5 
3-OHPTMA-iodide complex 
TLC spot corresponding to 
3-OHPTMA 
3-dimethylamino phenol 
3-OHNMP bromide 2.2 0.9 - 
3-OHNMP-iodide complex 
TLC spot corresponding to 
3-OHNMP 
3-hydroxypyridine 
(a) Temperature: injection, 3000 C; oven, 2000 C; detector, 3000C. 
Gas flow rates: nitrogen (carrier), 30m1/min; hydrogen 
2ml/min ; air 100m1/min. 
(b) British Pharmacopeia (1968) specification for GLc analysis. 
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2. GLC ANALYAIS OF PARENT DRUGS AND METABOLITES 
The respective retention times, symmetry factors and 
resolution of the parent drugs (neostigmine and pyridostigmine) 
were described by Chan et al. (1976). Fig 3.3 shows the 
chromatogram of neostigmine and pyridostigmine at 5ng/ml level. 
Table 3.1 and Fig 3.4 summarize the performance of GLC 
system for the analysis of the metabolites (3-OHPTMA and 
3-OHNMP). The retention times of these compounds indicated 
that 3-OHPTMA and 3-OHNMP (either as the bromide salts, or as 
the extract from TLC spots, or as the iodide ion complexes) 
were thermally decomposed at the injection pert to their 
corresponding tertiary analogues, 3-dimethylaminophenol and 
3-hydroxypyridine respectively, which were resolved by the 
GLC system. The mechanism of thermal dequaternization of 
the parent quaternary amines has been discussed in detail by 
Chan et al., (1976) and Chan (1980). 
The reproducibility of dequaternization at the injection 
port, where a glass liner was inserted, indicated that the iodide 
complexes of neostigmine and pyridostigmine yielded tertiary amines 
which gave linear peak area ratios with their corresponding internal 
markers over the range of 5- 100ng/ml (Fig 3.5). Similarly, 
results were obtained for the analysis of the metabolites over the 
range of 50 -1000äg/ml (Fig 3.6). These graphs were found to 
be reproducible when repeated five times during the studies. 
APPLICATION 
The procedure has been used to measure the concentration of 
pyridostigmine in human plasma after a single intravenous injection 
-75- 
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of the anti-ChE to twenty-five patients, that is described in 
detail in Chapter 4. 
DISCUSSION 
This method (Method 1) is a selective and sensitive 
procedure for the isolation and subsequent determination of 
some clinically useful anti-ChE and their major metabolites. 
Most previously published methods based on spectrophotometric 
detection, were not sensitive enough to measure these 
quaternary amines. Methods based on thermal dequaternization 
have been reported for a number of quaternary compounds, 
including acetylcholine (Szilazyi et al., 1972), thiazinamium 
(Jonkman et al., 1974) and neostigmine and pyridostigmine (Chan 
et al., 1976; Pohlmann and Cohan, 1977). Pohlmann and Cohan 
P 
(1977) in their report used methyiodide (part of dequaternized 
products) as a measure of quaternary amines in the plasma. 
However, this method suffers from the lack of selectivity 
as other quaternary compounds may also be ion-pair extracted 
and similarly assayed. The procedure described above measures 
apparently, specifically the dequaternized tertiary analogues. 
During the separation of major metabolites from their 
parent compounds, the phenolic OH groups of the 3-hydroxy 
metabolites tend to ionize at alkaline pH. Thus, Step 2 in 
the general Scheme (Fig 3.1) preferentially extracts the parent 
drugs. Barber et al., (1972) demonstrated that 3-OHPTMA, the 
major metabolite of neostigmine, was not extracted at pHlO 
using tetraphenyl boron sodium as the counter Lou, They 
were able to separate neostigmine and 3-OHPTMA at two different 
pH ranges. 
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The treatment of all glassware with silylafing agent was 
found to be essential to increase recoveries of drug. This 
is a generally accepted procedure for working with drugs at 
low concentration. 
This method was subsequently published (Chan and 
Dehghan 1978). 
METHOD 2 
THE SIMULTANEOUS DETERMINATION OF NEOSTIGMINE AND PYRIDOSTIGMINE 
IN HUMAN PLASMA AND URINE 
INTRODUCTION 
The anticholinestrase agents, neostigmine and 
pyridostigmine, are the most widely used compounds in the 
treatment of myasthenia gravis. A recent review has indicated 
that the monitoring of plasma levels of the anti-ChE agents 
may have considerable value in the pharmacotherapy of myasthenia 
patients (Chan 1980). Previously published GLC methods 
(including Method 1 described in page 64 ) for the determination 
of these drugs can only measure one drug at a time while the 
other is used as an internal marker (Chan at al., 1976 and 
Chan and Dehghan 1978). 
Recently, Aquilonius et al., (1979) reported an identical 
extraction procedure using deuterated (d6) neostigmine as-the 
internal standard and mass spectrometer (MS) as the detector 
for the determination of neostigmine in plasma. But the use 
of a GC-MS system is not always available in every laboratory, 
due to the high cost of such a system. The method (Method 2) 
--78- 
describes the syntheses of a series of pyridostigmine analogues 
and the development of one for use as a common internal standard 
for assaying neostigmine and pyridostigmine in plasma 
simultaneously. 
MATERIALS AND METHODS 
The method and materials described for the determination 
of anticholinesterase drugs (Method 1) in plasma was used 
with the following modification. The injector and detector 
temperature was increased from 300 to 350°C, and column 
temperature increased from 200 - 2200C to 2250C. Other 
materials used were: TLC plate coated with silica gel 0.15mm 
thick (Schleicher and Schull, Dassel, W. G. ) and analogues of 
pyridostigmine (synthesized in own laboratory). 
SYNTHESIS AND CHARACTERIZATION OF PYRIDOSTIGMINE ANALOGUES 
Various analogues of pyridostigmine bromide were 
synthesized in three stages. 
1. The synthesis of acid chlorides (CICONR2) was carried 
out according to Werner (1919). Dibutylamine, diethylamine 
or dipropylamine, equimolar with pyridine, was added to 
phosogene (127. in toluene i. e., in excess) at 0°C. The 
reaction by products were removed as follows Pyridine 
hydrochloride by filtration and phosogene, toluene and pyridine 
by evaporation. The residual yellow acid was micro-distilled 
under vacuum to give the carbonyl chlorides (about 607. yield) 
and the corresponding ureas were distilled at a high temperature. 
-79- 
The boiling points at 4mm Hg of diethyl, dipropyl and dibutyl 
carbonyl chlorides were 55°C, 88°C and 104°C respectively. 
2. The carbamates of 3-hydroxypyridine were synthesized 
according to Wurst and Sakel (1951). The 3-hydroxypyridine 
was dissolved in warmed toluene by stirring. The appropriate 
acid chloride was added in 1.25fold excess. The reaction was 
started by adding triethylamine, equimolar with the acid 
chloride and the mixture was stirred under reflex for four 
hours. At the end of the reaction, the triethylamine 
hydro chloride was removed by filtration and the toluene by 
evaporation and the colourless residual oil was micro-distilled 
under vacuum to yield the appropriate 3-pyridyl-nsn-dialkyl 
carbamates. 
The characterization of the tertiary analogues are 
summarized in Table 3.2. 
3. The quaternization of the tertiary analogues from 
Stage 2 (see Table 3.2) was carried out by reacting 
bromomethane (in excess) to toluene with the 3-pyridyl-n, n- 
dialkyl carbamates at room temperature. The quaternary 
bromide was partitioned into water. Toluene and water were 
initially removed by evaporation under vacuum and final 
products were dried over phosphorous pentoxide. White 
deliquescent crystals were produced, which were crystallized 
from dry ether/ethanol (1: 1) mixture and stored in dissicator 
before use. 
The products at each of the three synthesis stages were 
characterized by the measurement of boiling points at 4mmHg 
infrared spectrometry (IR), gas chromatography (GC) or thin- 
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layer chromatograph (TLC). The characteristics of the 
products of Stage 3 are summarized in Table 3.3. 
From these analogues, NsN-dipropylcarbamoyloxy-l-methyl- 
pyridinium bromide was considered the most suitable compound 
for use as a common internal marker for the simultaneous 
determination of neostigmine and pyridostigmine in human 
plasma. 
SIMULTANEOUS DETERMINATION OF NEOSTIGMINE AND PYRIDOSTIGMINE 
A procedure similar to the one described earlier (determination 
of neostigmine in page 66 ) was carried out for measuring of 
neostigmine and pyridostigmine simultaneously, using the bromide salt of 
N, N-dipropylcarbamoyloxy-l-methylpyridinium as the internal 
marker. 
The concentration of both drugs present in a sample was 
determined from the ratio of the integrated peak area to that 
for the internal marker. A corresponding calibration graph 
was prepared by adding a known amount of the drug to drug-free 
plasma (3m1) covering the range of concentration between 
5.0ag to 100. Ong/ml base, using 50ng/ml base of the internal 
marker (Fig. 3.9). The whole procedure of the assay is 
summarized in Scheme (Fig 3.7). 
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STEP 1 
Plasma (3m1), 150ng internal ma 
20µl 5N NaOH solution (pH-11) 
2x 6ml diethylether 
Discard diethylether to 
remove basic drugs and 
lipid soluble substances 
STEP 2 
Aqueous phase, Lml potassium 
iodide glycine, buffer (pH 11) 
2x 6m1 dichloromethane 
Evaporate organic extract 
to dryness, redissolve 
residue with methanol 
(20p1) GC determination 
for anti-ChE drugs (2u1) 
FIG 3.7 
A SUMMARY OF THE ASSAY PROCEDURE FOR NEOSTIGMINE AND 
PYRIDOSTIGMINE IN PLASMA 
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TABLE 3.2 
CHARACTERIZATION OF 3-PYRIDYL-NON-DIALKYL CARBAMATES 
0R 
II V 
/- 0-- C-N 
IýR 
COMPOUND BOILING IR GC RETENTION TLC Rf* 
POINT (CARBONYL TIME VALUES (AT 4mmgHg) RESONANCE) (min) 
A. R-C2H5 136°C 1720 2.8 0.86 
B. R-C3H7 144°C 1725 4.8 0.89 
C. R-C4H9 1680 C 1725 7.8 0.91 
* TLC Silica gel plates, developing system consisting of 
methanol: strong ammonia solution: butan-2-one (15: 20: 60). 
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RESULTS 
CHARACTERIZATION OF PYRIDOSTIGMINE ANALOGUES 
Table 3.2 summarizes the boiling points (at 4mm Hg), the 
IR characteristics (carbonyl resonance), GC retention times and 
TLC Rf values of the tertiary bases which were subsequently 
quaternized to yield the corresponding pyridostigmine analogues. 
It is interesting to note that when these tertiary analogues were 
run on a non-polar TLC plate (polyamide) their Rf values (0.97) 
were indistinguishable. Table 3.3 illustrates the GC and 
TLC characteristics of neostigmine (E), pyridostigmine (A) and 
the three synthesized pyridostigmine analogues (B, C and D). 
Thus, Compound C, the dipropylcarbamoyloxy analogue was chosen 
as the common internal marker for the simultaneous determination 
of neostigmine and pyridostigmine. 
SIMULTANEOUS GC ASSAY OF NEOSTIGMINE AND PYRIDOSTIGMINE IN PLASMA 
The respective retention times, symmetry factors and 
resolution of neostigmine, pyridoatigmine and the chosen 
internal marker are summarized in Table 3.4 Figure 3.8 
shows the chromatogram obtained in the analysis of plasma 
samples containing 100ng/ml of the drugs. The mean 
recoveries of neostigmine and pyridostigmine were 947. and 
937. (at 60ng/ml level) respectively. The reproducibility of 
dequaternization at the injection port , where a glass liner 
was inserted, indicated that bromides or iodide complexes of 
neostigmine , pyridostigmine and internal marker yielded their 
corresponding tertiary amines, which gave linear peak area ratios 
-84- 
TABLE 3.3 
GC and TLC CHARACTERISTICS OF PYRIDOSTIGMINE ANALOGUES 
/0 ýR 
-0- C-N 
R 
CH3Br 
COMPOUND GC RETENTION TLC Rf 
TIME 
(Minutes) VALUES* 
A. Rs CH3 2.2 0.83 
(pyridostigmine) 
B. R- C2H5 2.8 0.88 
(diethylcarbamoyloxy analogue ) 
C. R- C3H7 4.4 0.90 
(dipropylcarbamoyloxy analogue ) 
D. R- C4H9 7.8 0.93 
(dibutylcarbamoyloxy analogue ) 
E. Neostigmine 8.0 0.86 
(3-dimethy icarbamoyloxyphenyl 
trimethyl ammonium bromide) 
* TLC - Polyamide plates, developing solvent system consisting 
of methanol: strong ammonium solution: butan-2-one (15: 20: 60). 
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TABLE 3.4 
PERFORMANCE OF THE GC SYSTEM (107. OV-17 ON CHROMOSORB W-AW 
100-120 MESH)(a) 
COMPOUND IN METHANOL RETENTION SYMMETRYb) RESOLUTION 
TIME FACTORY BETWEEN 
(min. ) (0.95- MARKER 
(b) 
1.05) (> 1.0) 
Pyridostigmine bromide 
or iodide-complex 2.2 0.96 2.5 
Dipropyl analogue 
bromide or iodide complex 4.4 1.0 
Neostigmine bromide or 
iodide complex 8.0 1.0 3.75 
(a) Temperature: injection port 3500 C; oven 225; 
detector 350°C; gas flow rates: nitrogen (carrier gas), 
30ml/min; hydrogen, 2m1/min; air 100m1/min. 
(b) British pharmacopeia (1973) specification for GC 
analysis. 
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Typical chromatogram of plasma extract containing pyridostigmine (P)q 
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2.0 
1.0 
0 
pG 
IM 
90 W 
a 
Concentration (ng/m1) 
FIG 3.9 
Calibration graphs of neostigmine (neo) and pyridostigmine (pyr) 
using a common internal marker; (0), methanolic solutions of the 
drugs; (") plasma extracts of the drug-iodide complexes. Each 
point represents the mean of six experiments. 
20 40 60 80 100 
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over the concentration range between 5 to 100ng/ml (Fig 3.9). 
These graphs were found to be reproducible when repeated six 
times. 
DISCUSSION 
The determination of plasma concentrations of neostigmine 
and pyridostigmine simultaneously using a common internal 
marker (N, N-dipropylcarbamyloxy-l-meth ylpyridinium bromide) 
was based on the ion-pair extraction of the quaternary 
ammonium compounds into dichloromethane. The organic 
extract was analyzed by a gas chromatographic procedure. The 
GC quantitation depends on complete dequaterization of the 
quaternary amines, either as the bromide or as the iodide- 
complexes, to their corresponding tertiary analogues, which 
are then resolved by the GC system. 
'This was achieved by applying a high temperature (350C) 
° 
in the injection port to ensure complete pyrolysis of the 
quaternary moieties. A mechanism for this thermal 
decomposition of this group of quaternary compounds was 
suggested in a review by Chan (1980). 
The present assay procedure allows the simultaneous 
monitoring of the plasma levels of neostigmine and 
pyridostigmine when both of these anti-ChE agents are used 
for pharmacotherapy of myasthenia gravis. The technique 
can detect as low as lng/ml of the drug in a 3m1 plasma or 
urine sample, but accurate measurement is achieved within the 
range of 5 to 100n&/ml or higher. 
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The evidence of intersubject variations in the 
absorption of neostigmine (Aquilonius et al., 1979) and 
pyridostigmine (Calvey et al., 1977) suggests that the 
simultaneous monitoring of both of the anti-ChE agents in 
plasma should be important, as there is a lack of information 
concerning the effect of combined treatment with neostigmine 
and pyridostigmine in myasthenia gravis. 
This procedure has been used to measure the concentration 
of neostigmine and pyridostigmine in the plasma of seventeen 
myasthenic patients, who were treated with both drugs 
119 (combined dose). For more detail see Chapter 6 (page 120, 
Part of this work was presented at the British Pharmacological 
Society Meeting (1979) and later on published (Davison et al., 
1980). 
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CHAPTER IV 
DOSE DEPENDENT KINETICS OF INThAV NOUS PYRIDOSTI NE IN 
, SURGICAL PATIFNTS. 
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INTRODUCTION 
In anaesthetic practice, anti-ChE drugs are widely used to 
reverse non-depolarising neuromuscular blockade. In Great 
Britain, neostigmine methylsulphate (Prostigmine) is most 
commonly employed for this purpose. Occasionally pyridostigmine 
bromide is used, since its duration of action is approximately 
30% longer than neostigmine (Miller et al., 1974), and it has 
been suggested that it is less likely to induce significant brady- 
cardia Katz(1967). 
The plasma concentration of pyridostigmine was measured 
after three different doses of the quaternary amine (36.2pg/kg, 
72.4pg/kg and 144.8pg/kg) were given to 23 surgical patients during 
general anaesthesia. The relation between the plasma concentration 
of pyridostigmine and time was invariably expressed as a bi- 
exponential equation, and the data was interpreted in terms of 
a two compartment mammillary pharmokinetic model (Fig 4.1). 
PATIENTS AND METHODS 
Studies were carried out in twenty-three patients during 
the plastic surgical procedure. The subjects were 16 - 64 
years old and their body weight ranged from 49.9 - 93.4kg 
(see Appendix 4.1). 
, 
None of the patients had any clinical 
evidence of pre-existing hepatic or renal disease and the results 
of pre-operative haematological and biochemical assessment 
(i. e., haemoglobin and full blood count, plasma electrolytes, 
urea, creatinine, uric acid, inorganic phosphate, calcium, 
{ron, bilirubin, albumin, globulin and aminotransferase) were 
usually within normal limits (Approximately 10% of the 
-93- 
FIGURE 4.1 
THE TWO-COMPARTMENT OPEN MODEL 
K12 
K21 
Tissue or 
peripheral 
The drug is administered into the central compartment by 
rapid intravenous injection. K 12 and K21 are the first- 
order distribution rate constants and K10 is the first-order 
elimination rate constant. 
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results of biochemical assessment were slightly outside the 
normal range and the significance of these results is a matter 
of conjecture. ) One subject (Patient 2) was receiving 
concurrent treatment with anticonvulsant drugs (phenytoin 
sodium 300mg/day and phenobarbitone 90mg/day). All the 
patients were premedicated with nitrazepam (10mg orally given 
on the previous night). 
In studies using low or medium doses of pyridostigmine i. e ., 
36.2 -}ig/kg(200n mol/kg) or 
72.4p&/kg (400n mol/kg), anaesthesia 
was induced by thiopentone sodium (200 - 400mg); suxametin nium 
bromide (100mg) with tubocurarine chloride (15mg) was used 
for intubation. Anaesthesia was maintained with nitrous 
oxide (60 - 707. ) and halOtane (1 - 27. ) in oxygen, using 
intermittent positive pressure ventilation. During the 
course of the operation, a polyethylene can la was placed in a 
superficial vein, attached to a three-way tap, and kept 
patient by the infusion of saline. Pyridostigmine (36.2 pg/kg 
or 78.4 pg/kg) was injected intravenously as the bromide 
salt over a 15 second period. Blood samples approximately 
8ml were removed at 2,3,4,5,7,10,15,20,30,40,50, 
60,70,80,90,100,120 and 140min., and kept in lithium 
heparin blood tubes. 
In other studies, higher doses of pyridostigmine 144.8pg 
(800n mol/kg) were used to antagonise non-depolarizing 
neuromuscular block. In these conditions, anaesthesia was 
induced by thiopentone sodium (200 - 400mg), followed by 
tubncurarine chloride (45mg), and maintained with nitrous 
oxide (60 - 70%) and halothane (0.5%) in oxygen. At the end 
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of the operation, a polyethylene cannula was placed in a 
superficial vein as described above, and neuromuscular block 
was reversed by pyridostigmine (144.8 pg/kg) administered as 
the bromide salt and atropine sulphate (1.2mg). Blood samples 
approximately 8ml were usually removed at 2,3,4,5,7,10,15,20, 
40,60,80,100,120,140,160 and 180 min., and kept in lithium 
heparin. 
In all experiments plasma was removed from blood samples 
as soon as possible by centrifugation and stored at -200C 
before analysis. 
CALIBRATION GRAPHS AND DETERMINATION 
Two calibration graphs were prepared (using method 1 
page 61+ ), by adding known amounts of pyridostigmine bromide 
to 3m1 of drug-free plasma, covering the concentration range 
5.0 to 100. Ong/ml base, and 100.0 to 1000. Ong/ml base, using 
neostigmine bromide (50ng/ml base and 200ng/ml base 
respectively) as the internal standard (Fig 4.2. a, b). 
Pyridostigmine was extracted from plasma of surgical patients 
as an iodide-'complex, and its concentration for three different 
doses (200,400 and 800nmol/kg or 36.2,72.4 and 144.8pg/kg 
respectively) was determined by GLC method 1(page 64 ) and 
the results are summarized in Appendix 4.2; 4.3; and 4.4; 
respectively. 
RESULTS 
After intravenous injection of lower doses of pyridostigmine 
(36.2p&/kg or 72.4pg/kg), the unchanged drug was rapidly 
-"96- 
eliminated from plasma (Fig. 4.3.; 4.4; 4.6). In these studies, 
only trace amounts of pyridostigmine were detected after 90 
minutes (patients 8,12 and 16; Appendix 4.2; 4.3). By 
contrast, after larger doses of pyridostigmine (144.8pg/kg) 
significant concentrations of the drug (16 - 21ng/ml) were still 
detectable in plasma after three hours (Fig 4.4; Fig 4.5; 
Appendix 4.4). 
In all experiments, there was an initial rapid fall in the 
concentration of the unchanged drug, followed by a slower 
decline. The relation between the plasma concentration of 
pyridostigmine and time was invariably expressed as a 
biexponential function equation of the form 
C Ae- Mt+Be- pt 
p Equation (19) 
using non-linear least-square regression analysis (Appendix 
4.5; 4.6; and 4.7) where Cp is the plasma concentration at 
time t, and A, B, a and P are constant. Values for the 
fast disposition half-life (T/ a) and the slow disposition 
half-life (T 0) were derived from each biexperiential equation 
and interpreted in terms of a two compartment mammillary 
pharmacokinetic model (Fig 4.1). The parameters of the model 
were determined by standard method described in Chapter II and 
summarized in Appendix 4.8; 4.9; 4.10. 
After intravenous injection of pyridostigmine (36.2µg/kg), 
the fast disposition half-life of the drug was 1.00 + 0.12 
min. (mean + SE), and its terminal half-life was 22.79 + 
2.09 min. (Table 4.1). The volume of distribution (Vd) of 
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pyridostigmine (530.845 + 62.044 mi/kg) was generally greater 
than presumptive values for extracellular fluid volume and the 
clearance (C) was 16.252 + 1.550 ml/min/kg (Table 4.1). In 
the one subject (Patient 2) studied, these kinetic parameters 
were not apparently affected by concurrent therapy with 
phenytoin and phenobarbitone. 
After higher doses of pyridostigmine (72.4pg/kg), the fast 
disposition half-life almost doubled to 1.96 + 0.44 min. and 
the clearance increased to 21.324 + 0.820 ml/min/kg. 
Differences between the other kinetic parameters were not 
statistically significant (Table 4.1). By contrast, after 
the highest dose of pyridostigmine (144.8pg/kg), different 
results were obtained. The fast disposition half-life 
(1.01 + 0.30 min. ) was similar to the values after the 
lowest dose of pyridostigmine, although the terminal half- 
life (46.41 + 6.50min. ) was significantly greater (Table 4.1). 
In two patients (Patients 6 and 10 or 18 and 17 see Appendix 4.1) 
different doses of pyridostigmine (i. e., 36.2pg/kg and 144.8pg/kg) 
were given to the same subject on separate occasions. In 
both instances the slow disposition half-life was clearly 
prolonged after the larger dose of pyridostigmine (Fig 4.7). 
In addition, the total body clearance was significantly 
decreased (to 8.744 + 1.499m1/min/kg) although the other kinetic 
parameters were not significantly affected (Table 4.1). 
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DISCUSSION 
If pyridostigmine is distributed and eliminated by first-order 
processes, the half-life of the drug should be independent of the 
intravenous dose. However, in the present study the slow 
disposition half-life of pyridostigmine was progressively 
prolonged (from 22.79 + 2.09 min, to 46.41 + 6.50min) as the dose 
of the drug was raised from 36.2pg/kg to 144.8pg/kg. The 
increase in the terminal half-life of pyridostigmine was also 
observed in crossover studies in which different doses of the 
drug were administered to the same patient on separate occasions. 
The explanation for this phenomenon is obscure. The slow 
disposition half-life of pyridostigmine is dependent on the 
volume of distribution and the total plasma clearance of the 
drug, and it is difficult to relate the progressive increase in 
the half-life of the quaternary amine to corresponding changes 
in these primary kinetic parameters. Thus, there was no 
significant change in the volume of distribution of 
pyridostigmine as the dose of the drug was increased; by 
contrast, the clearance of the quaternary amine was enhanced 
at intermediate dose levels (i. e., 72.4pg/kg) but significantly 
reduced at high doses (144.8pg/kg). Cronnelly at al. (1980) 
have recently studied the kinetics of a two fold higher dose of 
pyridostigmine (350pg/kg), administered over a two minute period 
in patients with normal and impaired renal function. Values 
for the slow disposition and fast disposition half-lives of the 
quaternary amine in patients with normal renal function were 
longer than those observed in the present study, although the 
plasma clearance was similar. In both studies, the volume of 
-106- 
distribution was greater than that presumptive values for 
plasma or extracellular fluid volume. 
Although the interpretation of the results is difficult, 
and their significance is a matter of conjecture, they may 
partially account for the observed differences in the duration 
of action of neostigmine and pyridostigmine in man (Miller et al., 
1974). These differences are difficult to explain on 
pharmacodynamic grounds, since both quaternary amines are 
closely related chemically and inhibit junctional acetylcholines- 
terase in an idential manner (i. e., by carbamylation of the 
esteratic site on the enzyme). Thus, neostigmine and 
pyridostigmine produce the same inhibited enzymes with a half- 
life of recovery of approximately 30minutes (Wilson I. B., et al., 
1961; Wilson I. B., 1966; Kitz, 1964). When the kinetics of 
the lower dose of pyridostigmine (200nmol/kg) were compared 
with the results of equimolar doses of neostigmine (i. e., 206 - 
308 nmol/kg) during the reversal of neuromuscular block (Calvey, 
et al., 1979), it is clear that there are two important 
differences in the kinetics of the quaternary amines. 
In the first place, the volume of distribution of pyridostigmine 
530.845 + 69.044 ml/kg; mean + SE) is greater than 
neostigmine (122.21 + 46.62 mlkg mean + SE), reflecting its 
more extensive distribution and enhanced tissue up-take. 
Secondly, the clearance of pyridostigmine (16.252 + 1.550 ml/min/ 
kg; mean + SE) is at least five times greater than neostigmine 
(3.15 + 0.808 ml/min/kg; mean + SE); this difference is 
presumably related to the differential renal elimination of the 
two quaternary amines, since pyridostigmine is less extensively 
-107- 
metabolised than neostigmine (Sa mani et al., 1972). Similar 
results have been observed in experimental animals (Baker 
et al., 1978), and probably reflect differential steric and 
ionic properties of the two quaternary amines. In 
consequence, the elimination half-lives of pyridostigmine 
(22.79 + 2.09 min; mean + SE) and neostigmine (25.46 + 2.74 min; 
mean + SE) were similar and the difference between the mean values 
was not statistically significant (t - 0.777; 0.50>P>0.40). 
However, when these drugs are used in anaesthetic practice to 
reverse non-depolarizing neuromuscular block, the dose of 
pyridostigmine is normally 4 to 5 times greater than 
neostigmine, due to differences in the affinity of their quaternary 
groups for the anionic site on acetylcholinesterase. In these 
conditions, the slow disposition half-life of pyridostigmine may be 
prolonged, allowing significant recarbe mylation of acetylcholine- 
esterase to occur, and thus increasing the duration of action of 
the drug. 
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INTRODUCTION 
Neostigmine methylsulphate has been used in the treatment 
of myasthenia gravis for more than forty years (see Chapter I 
page 19 and Chapter 3 page 51 ). In addition, the drug is 
widely used in clinical anaesthesia to antagonise the effects 
of muscle relaxants after operative surgery. In these 
conditions, the clearance of the drug from plasma has been 
studied using a novel gas-liquid chromatographic technique 
(see page 68)- After rapid intravenous injection, neostigmine 
was eliminated in a biexponential manner, the fast disposition 
half-life (t/ a) of the drug was invariably less than one 
minute and the slow disposition half-life (t ranged from 
15.4 - 31.7 minutes (Calvey at al., 1979). 
In general, these results have been confirmed by the 
subsequent work of others. For instance, an identical gas- 
liquid chromatographic procedure (using a mass spectrometer as 
a detector) has confirmed that neostigmine is rapidly eliminated 
from plasma after intravenous injection, although slightly 
different values for the slow disposition half-life were 
obtained (Aquilonius et al., 1979). 
Both of these studies were based on the measurement of 
neostigmine in plasma during the antagonism of neuromuscular 
block. In the present work we have studied the kinetics and 
metabolism of the drug in plasma after its intramuscular 
administration to patients with myasthenia gravis. 
Intramuscular neostigmine methylsulphate is frequently used 
during diagnosis or initial therapy of myasthenic patients, and 
-111- 
knowledge of its kinetics in these circumstances may well be 
of clinical significance. 
METHODS AND PATIENTS 
Studies were carried out in five myasthenic patients who 
had a classical history of voluntary muscle fatiguability for 
periods of two months to two years. In most subjects, there 
was characteristic electromyographic decrement in response 
to the indirect stimulation of the affected muscle, and a 
positive response to edrophonium chloride ('Tensilon') was 
obtained. None of the patients was concurrently taking 
other compounds or was on anticholinesterase drugs. 
EXPERIMENTAL PROCEDURE 
In five patients, neostigmine methylsulphate (2.0mg) and 
atropine sulphate (0.6mg) were given simultaneously by 
intramuscular injection. Samples of blood were usually removed 
by venepuncture at 15,30,60,90,120,150,180 and 240 min. 
Plasma was obtained by centrifugation and stored at 
-20°C before analysis. The concentration of neostigmine in 
plasma was measured by gas-liquid chromatography using a 
nitrogen sensitive detector and pyridostigmine bromide 
(50it0ng/ml base) as the internal marker (see Chapter III 
page 68 ; and Figure 3.5). 
RESULTS 
In two myasthenic patients, neostigmine was detected in 
plasma within 15 minutes of intramuscular injection (Figure 5.1; 
-112- 
Table 5.1). The drug was not present until 3D minutes after 
administration in the other three subjects, and the plasma con- 
centration declined from 21 
12 ng/ml (mean S. E. M. ) to 9±1 ng/ml 
mean 
± S. E. M. ) between 30 minutes and 120 minutes. In three 
patients the neostigmine level was low at 150 minutes; in one of 
these subjects, the drug was still detectable at 180 minutes. No 
quaternary amine could be detected in plasma at 240 minutes (Table 5.1). 
The decline in the plasma concentration of neostigmine after 
intramuscular injection was interpreted in terms of a one compartment 
model (Gibaldi, 1975). Estimates of the half-life (ti) of the drug 
were obtained from a semilogarithmic plot relating the plasma con- 
centration of neostigmine to time between 30 and 150 minutes (The 
results obtained at 15 and 180 minutes were disregarded, since they 
were only obtained in a minority of the patients studied and were 
usually inconsistent with the trend of the other data points. ) In 
the five patients studied, the half-life of neostigmine ranged from 
56.9 - 100.1 minutes, corresponding to an apparent first-order elimina- 
tion rate constant (K) of 0.0122 min 
1 
to 0.0069 min-1 (Table 5.2). 
The extrapolated concentration of neostigmine at zero time (Co) was 
used to determine the total apparent volume of distribution V,,,, from 
equation (7) in Chapter II (page33). 
V_ dose 
(as neostigmine base) 
C 
0 
Values for the total apparent volume of distribution varied. from 
35.2 - 63.0 litres. Corresponding values for total body clearance 
as calculated from the product of Vd and K, ranged from 
-113- 
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FIGURE 5.1 
The plasma concentration of neostigmine in five myasthenic patients 
after intramuscular administration of the drug. Each symbol 
(", o. ". O and  ) represents the results obtained in five 
different subjects between 30 and 150min. The dotted lines 
indicate the extrapolation to zerotime with Co as concentration 
in tng/ml. 
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TABLE 5.1 
Plasma concentration of neostigmine (ng/ml) in five myasthenic 
patients following an IM dose of 2mg of neostigmine 
methylsulphate. 
TIME SUBJECTS 
12345 
0 
15 NS 32 NS 24 
30 26.9 20 19.2 18 18.5 
45 16.2 
60 17.9 15 14.1 12 13.5 
75 12.5 NS 
90 12.9 14.1 10.8 9.2 11.2 
120 8.6 11.1 8.4 7.5 9.3 
150 ND 5.2 NS NS 6.9 
180 NS NS NS NS 5.7 
240 NS NS NS NS NS 
ND - non detected 
NS - non sample 
-115-. 
TABLE 5.2 
Kinetic parameter of neostigmine after intramuscular 
administration. 
PATIENT tk K Vd Vd xK 
(min) (min-1) (L) (m1/mis) 
1 56.9 0.0122 35.2 429 
2 92.5 0.0075 53.2 399 
3 73.1 0.0095 53.2 505 
4 66.0 0.0105 59.3 623 
5 100.1 0.0096 63.0 435 
MEAN + 77.7 + 0.0093 + 52.8 + 478 + 
S. E. M. 8.1 0.0010 4.8 4.0 
biological half-life 
K elimination rate constant 
ýd total apparent volume of distribution 
Vd xK total body clearance 
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399 - 623 ml/min (Table 5.2). 
DISCUSSION. 
The present experiments show that neostigmine is rapidly 
absorbed and eliminated after intramuscular administration to 
patients with myasthenia gravis. In all the subjects studied, 
maximal concentrations (18 - 32ng/ml) were present in plasma 
between 15 and 30 minutes, although only small or undetectable 
concentrations were present after 120 minutes. Thus, the 
presence of detectable concentrations of the drug in plasma 
approximately corresponds to its duration of action in myasthenic 
patients. In the present experiments as well as in previous 
studies of Calvey et al. (1979) and Chan et al. (1976), 
the analytical method has been shown to detect neostigmine at 
concentrations of 5-7 ng/ml in the plasma, and can be used 
for the assessment of anticholinesterase therapy in man. Other 
authors (Aquilonius, 1979) suggested that the method only allows 
accurate measurement of neostigmine at concentrations above 
50 ng/ml, but this has not been shown in the present study. 
After intramuscular administration of neostigmine to five 
myasthenic patients, there was a monoexponential decline in the 
concentration of the drug in plasma between 30 and 120 minutes. 
When the results were interpreted in terms of a one 
compartment model, the half-life of the drug ranged from 56.9 - 
100.1 minutes, the apparent volume of distribution from 35.2 - 
63.0 litres. The half-life and intercept of the slow 
disposition phase was observed after intravenous injection of 
-117- 
neostigmine (Calvey, 1979). By contrast, there may be a 
forty-fold difference in plasma concentration in patients 
receiving oral neostigmine (Aquilonius 1979). Since this 
variability is not observed after intramuscular or intravenous 
neostigmine, it is presumably related to inter-individual 
differences in drug absorption and/or variation in the first- 
pass effect. As neostigmine is extensively metabolised in man 
the first-pass effect may be of considerable importance. 
The volume of distribution of neostigmine was approximately 
equal to total body water. Distribution studies in experimental 
animal suggests that the drug is extensively localized in 
extraceilular fluid, liver and kidney, but not in other tissues 
(Somani, 1975). The results of the present study are not 
inconsistent with this interpretation. Total body clearance 
of the drug ranged from 399 - 623 ml/min; these values are 
greater than the glomerular filtration rate, and suggest the 
occurrance of tubular secretion or extensive metabolism of 
neostigmine. 
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CHAPTER VI 
PART ONE 
PLASMA LEVIIß OF NFDSTIMWE AND PYRIDOS4IGHINE IN 
MYASTBr3VIC PATIENTS AFTER ORAL ADMINISTRATION. 
PART TWO 
THE RELATIONSHIP OF PLASMA LEVELS OF PYRIDOSTIGMINE 
TO CLINICAL EFFECT IN PATIENTS WITH MYAST KIA 
GRAVIS. 
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PLASMA LEVELS OF NIDSTIGMINE AND PYRIDOSTIM+ANE IN 
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INTRODUCTION 
Over the past forty years, anticholinesterase (Anti-ChE) 
agents such as neostigmine and pyridostigmine have been used 
as the first line of treatment for most patients with myasthenia 
gravis and pyridostigmine is the most widely used drug. 
However, only until recently disposition and pharmacokinetic 
studies of these agents have been carried out in man due to 
recent advance of analytical techniques. 
The metabolism of pyridostigmine in man was studied by 
Kornfeld et al., (1971) using 
14_C_ labelled analogue and by 
Somani and others (1972) using mass spectrometry. Cohen and 
colleagues (1976) monitored plasma concentration of 
pyridostigmine in myasthenic patients and demonstrated that 
there was a possible relationship between plasma levels of the 
drug and clinical response. Recently, Calvey and Chan (1977) 
have shown that there was a considerable variation in the 
bioavailability of pyridostigmine among six myasthenic patients 
and that the plasma concentration of the drug was invariably 
positively correlated with the improvement in neuromuscular 
transmission in patients with typical electromyographic decrement 
using the adductor pollicis.. 
The pharmacokinetics of neostigmine after intravenous 
administration to surgical patients during the reversal of 
neuromuscular block have recently been investigated 
(Aquilonius et al., 1979; Calvey et al., 1979). Both studies 
suggested that neostigmine was eliminated from plasma 
biexponentially. In a separate study on intramuscular 
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neostigmine in myasthenic patients, the kinetics were best 
described by a one compartment model (Soman& et al., 1980). 
However, there is no information on the kinetics of the two 
anti-ChE-agents when both neostigmine and pyridostigmine are 
used in severe cases of myasthenia gravis. Recently, we have 
developed a gas-liquid chromatographic method which can 
determine simultaneously the plasma concentrations of 
neostigmine and pyridostigmine using a synthesised pyridostigmine 
analogue, n, n-dipropylcarbamoyloxy-N-methyl pyridinium 
bromide, as a common internal marker (see Chapter III part 
the 
two). This part of1work is concerned with the concentration 
of these two anti-ChE drugs in the plasma of seventeen myasthenic 
patients who were stabilized either by pyridostigmine only, or 
on both neostigmine and pyridostigmine therapy. 
PATIENTS AND METHODS 
SUBJECTS 
Studies were carried out on eight myasthenic patients who 
were stabilized on varying amounts of oral pyridostigmine bromide 
only (appendix 6.1), and nine patients who were maintained by 
the oral administration of neostigmine and pyrido. stigmine (Appendix 
6.2 and 6.3). In conjunction with the anti-ChE treatment, some 
patients were also given predniso]A ne and azathioprine 
supporting therapy. 
PROCEDURE 
The dosage schedule of each patient was not modified during 
the study. Blood samples. (usually 10 ml) were removed by 
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venUpuncture at two hourly intervals after the initial morning 
dose (Appendix 6.4), during the waking day (8.00am to 8.00pm). 
The samples were kept in blood tubes containing lithium heparin 
and plasma was promptly obtained by centrifugation and stored 
at -20°C before analysis. 
DETERMINATION OF PLASMA CONCENTRATION OF THE ANTI-ChE DRUGS. 
The plasma concentrations of neostigmine and pyridostigmine 
were determined by the gas-liquid chromatographic technique 
described in Chapter III (page 80) using a co= wn internal 
standard n-n-dipropylcarbamöloxy-N-methyl pyridinium bromide. 
A corresponding calibration graph was prepared by adding 
known amounts of the drug to drug-free plasma (3ml), covering 
the range of concentrations between 5. Ong to 100. Ong/ml base 
using 50ng/ml base of the internal marker (Fig. 3.9 page 87 ). 
RESULTS 
PLASMA PYRIDOSTIGMINE 
Plasma levels of pyridostigmine were monitored from 8.00am 
to 8.00pm in eight myasthenic patients, who were stabilized on 
intermittent dosage from 60 to 540 mg orally. In these 
patients the maximum plasma concentration throughout the whole 
waking day ranged from 12.4 to 64.5n&/ml, and the minimum from 
1.3 to 25. Ong/ml (Appendix 6.5). Typical plasma profiles 
of pyridostigmine for patient 1 (lowest daily dose) and 
patient 5 (highest daily dose) are shown in Fig 6.1. The 
area under plasma concentration-time curves (AUC) of 
pyridostigmine in these patients ranged from 587.5 to 
4560.0ng/ml-1hour, over the twelve hour period (Fig 6.2). 
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TABLE 6.1 
Plasma concentrations and bioavailability of pyridostigmine 
between 8.00am and 8.00pm after oral administration of 
intermittent doses of pyridostigmine only. 
PATIENT DAILY DOSE OF MIN. and MAX. AREA UNDER 
PYRIDOSTIGMINE CONCENTRATION PLASMA CONCENTRATION- 
BROMIDE (mg per ml) TIME CUIVE 
mg (nit ml hr) 
1 60 1.3 - 12.4 587.5 
2 360 9.0 - 36.0 2920.0 
3 180 5.0 - 14.0 992.5 
4 300 11.0 - 40.0 3070.0 
5 540 20.5 - 64.5 4560.0 
6 360 25.0 - 40.0 3782.5 
7 480 24.0 - 39.0 3495.0 
8 240 6.2 - 23.0 1936.0 
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TAE BL 6.2 
Plasma concentrations and bioavailability of pyridostigmine 
between 8.00am to 8.00pm after oral administration of 
intermittent doses of neostigmine and pyridostigmine. 
PATIENT DAILY DOSE OF MIN. & MAX. CONCENTRATION AREA UNDER 
NEOSTIG- PYRIDO- of PLASMA 
MINE STIGMINE NEOSTIGMINE PYRIDOSTIGMINE CONCENTRATION- 
BROMIDE BROMIDE TIME CURVE 
mg mg (ng per ml) 
(pyridistigmine) 
_ 
(nit per ml) 
_ 
(nit/ml hr) 
9 150 240 ND 12.3 - 61.5 5276 
10 120 300 ND 8.5 - 33.0 2070 
11 180 360 ND 5.4 - 15.3 1034 
12 60 360 ND 50.0 -144.0 9140 
13 60 240 ND 5.5 - 60.0 3433 
14 90 360 ND 9.3 - 25.5 2137 
15 180 180 4.7 - 33.0 2.7 - 18.6 864 
16 15 1080 ND 11.0 - 36.5 3022 
17 480 810 ND 5.3 - 28.0 1956 
ND - not detected 
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When the AUC was plotted against the total daily dose of 
pyridostigmine for all eight patients a linear relationship 
was observed (Fig 6.3). 
PLASMA PYRIDOSTIGMINE AND NEOSTIGMINE 
In only one of the nine patients (patient 15) both 
neostigmine and pyridostigmine were detected in the plasma 
(Fig 6.4). In this group of patients, the plasma concentrations 
of pyridostigmine were higher and more diversified; the 
minimum range was 5.4 to 60. Ong per ml and the maximum range was 
15.3 to 144. Ong per ml (Table 6.2). No linear correlation 
between AUC of pyridostigmine and total daily dose was 
observed in this group of patients who received both 
neostigmine and pyridostigmine therapy (Fig 6.5). 
DISCUSSION 
In the present investigation, the eight myasthenic 
patients were stabilized on widely different daily dose of 
pyridostigmine (Appendix 6.3 and Table 6.1). Although the 
concentration of pyridostigmine in plasma, varied between 
12.4 to 64.5ßg/ml (maximum range) and 1.3 to 25. Ong per ml 
(minimum range) there was a direct relationship between the 
AUC and total daily dose of the drug in these eight patients over 
the twelve hour period of investigation. In an investigation 
on six myasthenic patients, the peak plasma concentration of 
the drug ranged from 44.2 to 84. Ong per ml; and in most cases 
the level was maintained between 20 to 60ng per ml in a period 
of eight hours, when the dose of pyridostigmine was between 
60 to 660 mg per day (Calvey and Chan 1977). These observations 
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suggest that the widely different dosage requirement of 
pyridostigmine in myasthenic patients may be partly related 
to intersubject variation in drug absorption and disposition 
and to varying severity of the disease. 
The presence and significance of intersubject variation 
in the oral absorption of pyridostigmine is difficult to 
demonstrate and assess. In a previous study, the AUC of 
pyridostigmine in 3 myasthenic patients was maintained in a 
narrow range four hours after the same oral dose of 60mg 
(Calvey at al., 1977) suggesting that absorption of the drug 
from the gut is relatively constant. In the present study, 
the plasma level of pyridostigmine was monitored over a longer 
period of time (up to twelve hours after the first oral dose), 
and there is a positively direct relationship between the 
AUC of pyridostigmine and total daily dose during this 
period, r=0.95 (Fig. 6.3). These observations are in 
direct contrast to that for one myasthenic patient, whose 
bioavailability of the drug was increased six fold by 
doubling the dose of pyridostigmine bromide from 30 to 60mg 
(Calvey at al., 1977). Perhaps there is also an intra- 
subject variation in the absorption of the drug. 
In general, quaternary amines cannot readily penetrate 
lipophilic cellular membranes in the gut, due to their complete 
ionization at all pH. Some quaternary amines are known to 
form ion-pair complexes with intestinal components such as 
mucin or bile salt, which are readily extracted into organic 
solvents (Levine and Clark 1957; Schanker, 1963). Thus, in 
the present experiments, there were frequent fluctuations in 
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the plasma concentration of pyridostigmine which were not 
apparently related to dosing intervals. These fluctuations 
were not observed after intravenous injection of the drug 
(see Chapter IV). In patient 1 (Fig. 6.1), there was a 
secondary rise in plasma concentration after a single dose of 
pyridostigmine bromide (60mg). This observations is 
consistent with previous observations (Calvey et al., 1977). 
The secondary rise may be related to the formation and 
absorption of lipophilic ion-pair complex although the actual 
mechanism of absorption of pyridostigmine is unknown. 
The processes of drug absorption and disposition, 
may be influenced by the presence of other drugs. The renal 
clearance of pyridostigmine was reported to be reduced by 
concurrent administration of some tertiary amines which are 
partially present as cations at physiological pH and may 
comp e, to with pyridostigmine for renal tubular transport 
(Chan and Calvey, 1978). Of the nine myasthenic patients 
(patients 9- 17, Appendix 6.3 and Table 6.2), who were 
maintained by both oral neostigmine and pyridostigmine therapy, 
only in patient 15 both drugs were detected in the plasma. 
Two possible explanations may be considered for this 
observation. Firstly, the bioavailability of neostigmine 
was estimated to be 1- 2% of the ingested dose and 
considerable interindividual differences in the absorption of 
neostigmine after oral ingestion of the drug were observed 
Aquilonius et al., (1979). The low bioavailability of oral 
neostigmine is probably due to its extensive metabolism by the 
liver after 'first-pass effect'(Somani et al., 1972). The 
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sampling procedure in the present study might have missed the 
peak concentration or the assay procedure was not sensitive enough 
to detect concentration approaching picogramme range. 
Secondly, the possibility of drug-drug intraction between 
neostigmine and pyridostigmine at the absorption phase should 
not be ruled out. There was no direct correlation between the 
AUC of pyridostigmine and total daily dose in these patients 
(9 - 17) who were treated with both anticholinesterase drugs 
(Fig. 6.5), compared with pyridostigmine only (Fig. 6.3). 
The highest and lowest concentration ranges of pyridostigmine 
in patients 9 to 17 were higher and more diversified than those 
of patients 1 to 8 (Table 6.1 and 6.2). When the AUCs 
of pyridostigmine of all seventeen patients were plotted 
against total daily dose of the drug, there was no correlation 
(r - 0.15). Thus, pyridostigmine appears to compete for oral 
absorption with neostigmine. Patient 15 was receiving the 
lowest daily dose of pyridostigmine (180mg) and in whom 
neostigmine was detected in the plasma (Fig 6.4, Table 6.2). 
These observations suggest that if there is a correlation 
between clinical response and plasma level of anticholinesterase 
drug in myasthenia gravis the concurrent administration of 
oral neostigmine and pyridostigmine may not benefit the 
patients. A combination of intramuscular and oral routes of 
these two quaternary amines may be more advantageous. 
However, further studies should be carried out to substantiate 
the present observations of interaction between neostigmine and 
pyridostigmine and to elucidate the mechanism of absorption 
of these drugs in the gut.. 
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PART TWO 
The relationship of plasma levels of pyridostigmine to 
clinical effect in patients with myasthenia gravis. 
ACKNOWLEDGEMENT: 
The clinical studies of global assessment of 
Muscle Power and fatigueability in myasthenic 
patients and the determination of antibodies 
in these patients plasma were carried out by 
Dr. Susan C. Davison in The Radcliffe Infirmary, 
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INTRODUCTION 
Pyridostigmine bromide (mestinon) is one of the main 
anticholinesterase drugs used in the treatment of myasthenia 
gravis (Drachman, 1978). Very little is known of the 
effective plasma concentration of the drug in myasthenic 
patients, although the daily dosage requirement may vary from 
30 to 2000 mg per day (Greene 1969). There was a possible 
relationship between plasma pyridostigmine levels and clinical 
response in myasthenia gravis (Cohen et al., 1976). 
Recently, Chan and Calvey (1978) showed that in four patients 
with typical electromyographic decrement in the adductor 
pollicis, the plasma pyridostigmine levels were directly 
related to the effect on neuromuscular transmission. 
The present study was undertaken to examine the 
relation between plasma levels of pyridostigmine and a global 
clinical evaluation of muscle power and fatigueability such as 
could be carried out during out-patient consultation. The 
discovery of a positive correlation between a global assessment 
of muscle power and plasma levels of pyridostigmine would be 
a valuable aid in optimising dosage schedules in individual 
patients. 
PATIENTS AND METHODS 
Two male and seven female patients between the ages of 
19 and 58 years with histories of myasthenia gravis of two 
to twenty-two years duration were studied; five of them 
had had thymectomies and three were being treated with 
prednisolone on alternate days. The total daily dose of 
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pyridostigmine ranged from 60 to 1080 mg (Table 6.3). 
A diagnosis of myasthenia gravis was made when two of the 
following criteria were fulfilled: - 
(a) A characteristic electromyographic response 
(Greene 1969). 
(b) A positive edrophonium test (Greene , 1969), 
and 
(c) An excess of auto antibody directed against human 
muscle acetylcholine receptors (Greene , 1969). 
None of the subjects was severely disabled by the disease 
and informed consent was obtained. 
Patients were admitted to hospital for a period of 
twenty-four hours and maintained on their normal drug regime 
during that time. All subjects rehearsed a routine of 
timed exercises in order to test a variety of different muscle 
groups for susceptibility to fatigue before starting the 
experiment. Details of the routine are summarized in 
Table 6.4 together with the end points. An individual 
test took a maximum of twenty minutes to complete, being 
terminated after two minutes if no fatigue occurred. The 
test was performed immediately before each blood sample was 
taken. Between the hours of 08.00 and 20.00ý(Appendix 6.5) 
venous blood samples (10ml) were taken at roughly two hours 
intervals, the sampling times occurring at one to four hours 
after an oral dose of pyridostigmine. Immediately after the 
blood sample was taken it was mixed with lithiumheparin in 
the blood tube and the plasma was separated by centrifugation 
and stored at -20°C before analysis. The concentration of 
-138- 
pyridostigmine was subsequently measured in duplicate by gas 
liquid chromatography (see Chapter VI, Part One). A small 
quantity of plasma set aside to measure the concentration of 
acetylcholine receptor antibody using acetylcholine receptor 
prepared from human calf muscle, labelled with 
1251-bungarotoxin 
as the antigen. 
RESULTS 
For each subject, each separate exercise testing a particular 
function was evaluated across all six trials in two ways; the 
trials were ranked 0 to 5 from worst to best performance and 
they were also rated on a continuous scale with best and worst 
set 10 and 0 respectively. The global assessment for each 
trial was simply expressed as the average rank or scale score 
calculated from the eight different tests. These were then 
plotted against plasma concentration of pyridostigmine in 
ng/ml (Fig. 6.6 and 6.7). 
Regression analysis demonstrated (using a computer program, 
Appendix 6.6) a trend towards a positive correlation between a 
global assessment of muscle powers and plasma concentration in 
five of the nine subjects (Fig 6.6), but in only two of them was showed 
significance at pG0.05 level (Patients 8 and 16). Of the 
remaining four, one showed a negative correlation at p 
<0.1. 
The findings are summarized in Table 6.5. No single test of 
function, e. g., vital capacity, correlated more closely with 
plasma drug level than the global assessment. 
Diurnal variation in plasma levels of pyridostigmine and 
global scores for muscle strength were observed in most subjects, 
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TABLE 6.4 
THE ROUTINE OF TIMES EXERCISES AND MEASURES USED TO ASSESS 
SUSCEPTIBILITY TO MUSCLE FATIGUE 
INSTRUCTION END POINT 
Look straight ahead and fix on an Widest part of the palpebral 
object at eye level fissure measured using a 
transparent rule 
calibrated in millimeters. 
While facing forward, fix eyes 
a point above your head. 
Diploplia or loss of 
fixation. 
Hold arms outstretched, 
horizontally from the 
shoulders. 
Grip with each hand in turn 
the inflated sphigmomanometer 
cuff as tightly as possible. 
Vital capacity 
While lying supine raise each 
leg in turn and hold it at 45° 
to the horizontal for as long 
as possible. 
While lying supine, raise the 
head off the bed and hold it 
there unsupported for as 
long as possible. 
Walk a distance of 75 yards, as 
fast as possible. 
When arms drop below the 
horizontal. 
When the pressure registered 
on the manometer drops to one 
half the maximum pressure. 
Best of three tries. 
When the heel touches the bed. 
When the occiput touches the 
bed. 
Crossing the finishing line. 
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TABLE 6.6 
The diurnal variation in plasma concentration of pyridostigmine 
and performance in the test routine, the average of the three 
measures before and after noon are compared. 
SUBJECT BEFORE NOON AFTER NOON 
PLASMA SCALE PLASMA SCALE 
LEVEL SCORE LEVEL SCORE 
1 10.7n&/ml 6.7 1.5ng/ml 3.9 
2 21 5.8 28 3.3 
3 12 6.8 7 6.0 
4 33.7 5.3 19.7 3.3 
5 44.6 5.7 37.5 4.4 
6 28.2 5.7 31.8 4.4 
7 33.2 5.3 29.7 5.1 
8 17.5 5.2 31.2 6.5 
16 20 5.5 16.6 3.4 
-1.43- 
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FIG 6.6 
Five patients showing trend towards more actual positive 
correlation between plasma levels of pyridostigmine and 
assessment of muscle strength. 
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both muscle strength and drug level being higher in the 
morning than in the afternoon (Table 6.6). 
DISCUSSION 
Studies of plasma levels of anti-ChE agents in myasthenia 
gravis are required since alteration of doses of oral anti- 
ChE drugs depend largely on the patient's own subjective 
response. The edrophonium test ( Green, 1969) 
to determine optimal dosage is frequently difficult to 
interpret because the effect varies at different times in the 
same day and on other occasions it may improve function of 
some muscles, but either does not alter or worsen the strength 
in others. It might, therefore, be predicted that similar 
difficulties would be encountered with the interpretation of 
serum levels when correlated to clinical signs. In addition, 
the pharmacokinetics of pyridostigmine are poorly understood 
and there is no good reason to predict that such a correlation 
should exist. Nevertheless, some previous studies suggest 
that a relationship between serum level and response may exist. 
in one such trial (Cohen, et al., 1976), 
nine myasthenic patients were examined at thirty minute intervals 
for six hours after drug administration, and improved motor 
strength subjectively was apparently parallelled by serum 
pyridostigmine concentrations, but the authors felt that the 
clinical response was not quantifiable. In another study 
(Calvey et al., 1977) wide variations in the oral dosage 
(60 to 660mg/day), nevertheless produced a relatively narrow 
plasma pyridostigmine range (20 to 60mg/ml). In an earlier 
study ( Chan and Calvey, 1977), four patients with 
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unsatisfactory control had lower serum levels than those who 
were well controlled. The strength of these patients improved 
when the serum pyridostigmine increased and they demonstrated 
that the original low levels were due to malabsorption. 
A further type of correlation was made on four patients with 
typical electromyographic decrements in adductor pollicis 
consistent with myasthenia gravis ( Chan and Calvey, 1977). 
There was a positive correlation between the concentration of 
pyridostigmine plasma and the effect of the drug on neuro- 
muscular transmission. In the present series of nine patients, 
a wide variety of exercises each testing particular functions 
was thought important, due to possible variations in the 
strength of different muscle groups in the same patient. 
In addition, the clinical responses were quantified satisfactorily. 
In only two subjects was there a significant correlation 
between muscle power and plasma concentration; three other 
patients showed apparent positive correlation. No single test 
of motor function correlated more closely with plasma drug 
level than the global assessment. In addition, the presence 
or absence of a possible correlation between muscle power and 
plasma concentration was not apparently related to the 
duration of the disease, addition prednisolonetherapy or 
thymectomy. 
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CHAPTER VII 
FINAL DISCUSSION 
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Chapter seven Page No. 
Determination of Anti-ChE drugs & metabolites in 
biological fluids. 149 
Kinetics of IV pyridostigmine in surgical patients. 151 
Kinetics of IM neostigmine. 162 
Oral neostigmine & pyridostigmine, & the 153 
correlation of clinical response to plasma 
pyridostigmine in myasthenia gravis. 
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DETERMINATION OF ANTI-ChE DRUGS AND METABOLITES IN BIOLOGICAL FLUIDS 
Quaternary amines in general, are strong bases which have 
pKa values approaching fourteen and are completely ionized 
in all biological fluids. Absorption from the gastrointestinal 
tract is incomplete and even neglible for certain quaternary 
ammonium compounds such as d-tmbocurarine, pancuronium and 
related neuromuscular blocking agents. 
Distribution in the body is usually restricted to the 
extracellular fluids as they traverse cell membranes with 
difficulty (Golstein 1974) and elimination is mainly by excretion 
of the unchanged drug in the urine or in the bile and also by 
metabolism in the liver (Dal Santo 1969). Thus, the chemical 
and distribution-elimination characteristics of quaternary amines 
will influence their extraction procedure from biological fluids. 
In general the measurement of drugs in plasma or urine 
samples after therapeutic doses involves a preliminary 
extraction of the drug into a suitable organic solvent. A 
subsequent concentration of the organic extract and the final 
measurement of the drug in the concentrate by a sensitive and 
selective instrumental technique. 
Most previously published methods, based on spectrophoto- 
metric detection, radio isotopic techniques and enzymatic 
procedures were not sensitive enough or selective and these 
investigations are expensive or time-consuming. Analysis based 
on gas-liquid chromatographic techniques have been used for the 
quantitation of pyridostigmine and neostigmine (Chan 1976). 
In the development of the method, treatment of all glassware 
with silylating agent was found to be essential to increase 
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recoveries of drug to 957, and 94% (at 60ng/ml level) for neostig- 
mine and pyridostigmine respectively (see Chapter III). 
The ion-pair extraction of neostigmine, pyridostigmine and 
their metabolites was proved to be specific using TLC and GLC 
methods. The extraction of parent drugs has been achieved at 
pH = 11, and the limit of quantitation is ing/ml using 10%OV17 
on chromosorb W-Aki. The extraction of the metabolites of 
neostigmine and pyridostigmine has been done using potassium 
tri-iodide as counter-ions at pH=4, and the quantitation is 
possible down to 50 ng/ml in urine using 3m1 samples. 
The synthesis of a series of pyridostigmine analogues and 
the development of one (N, N-, dipropylcarbomoyloxy-l-methyl 
pyridinium bromide) for use as a common internal standard for 
assaying neostigmine and pyridostigmine in plasma simultaneously, 
has also been achieved (Chapter III). The assay involved a 
preliminary ion-pair extraction of the drugs and the internal 
marker from plasma using potassium-iodide glycine buffer. The 
assay procedure allows the simultaneous monitoring of the 
plasma levels of neostigmine and pyridostigmine when both of 
these anti. ChE agents are used for pharmacotherapy of myasthenia 
gravis. The evidence of intersubject variations in the 
absorption of neostigmine (Aquilonius, 1979) and pyridostigmine 
(Calvey and Chan, 1977) suggests that the simultaneous monitoring 
of both of the Anti-ChE agents in plasma should be important, 
as there is a lack of information concerning the effect of 
combined treatment with neostigmine and pyridostigmine in 
myasthenia gravis. The methods developed in the present study 
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represented a significant improvement over those systems previously 
available. 
KINETICS OF IV PYRIDOSTIGMINE IN SURGICAL PATIENTS 
Neostigmine methylsulphate (prostigmin ) is one of the 
Anti-ChE drugs which is widely used to reverse non-depolarising 
neuromuscular blocks in anaesthetic practice. In the study of 
IV pyridostigmine (200 nmol/kg) compared with the kinetics of 
approximately equimolar doses of neostigmine (i. e., 206 - 
308 n mol/kg, Calvey et al., 1979), it is clear that there are 
two important differences in the kinetics of the quaternary 
amines; firstly, the volume of distribution of pyridostigmine 
(530.845 + 62.0 mean + SE) is greater than neostigmine (122.21 
+ 40.62, mean + SE) reflecting its more extensive distribution 
and enhanced tissue uptake. Secondly, the clearance of 
pyridostigmine (16.25 + 1.5, mean + SE) is at least five times 
greater than neostigmine (3.15 + 0.80 mean + SE); this difference 
presumably related to the differential renal elimination of the 
two quaternary amines. In consequence, the elimination half- 
lives of pyridostigmine (22.79 + 2.09, mean + SE) and neostigmine 
(25.46 + 2.74, mean + SE) were similar. However, when these 
drugs are used in anaesthetic practice to reverse non- 
depolarizing neuromuscular block, the dose of pyridostigmine is 
normally 4-5 times greater than neostigmine, perhaps due to 
differences in the affinity of their quaternary groups for the 
anionic site on acetylcholinesterase. 
The slow disposition half-life of pyridostigmine was 
progressively prolonged (from 22.79 + 2.09 min. to 46.41 + 
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6.5 min) as the dose of the drug was raised from 36.2 pg/kg to 
144.8 rg/kg. The increase in the terminal half-life of 
pyridostigmine was also observed in crossover studies in which 
different doses of the drug were administered to the same patients 
(see Chapter IV) on separate occasions. In addition, the total 
body clearance was significantly decreased (to 8.75 + 1.5 
ml/min/kg) although the other kinetic parameters were not 
significantly affected. 
KINETICS OF INTRAMUSCULAR NEOSTIGMINE 
Neostigmine was rapidly absorbed and eliminated after 
IM administration, maximal levels were reached in plasma at 
30 minutes but only small or undetectable amounts were present 
after 120 minutes (see Chapter V). The kinetic parameters 
obtained are based entirely on experimental ddta during this 
period. When the results were interpreted in terms of a 
1-compartment model, the elimination tý ranged from 56.9 to 
100.1 minutes and Vd from 35.2 to 6.5. OL., and the clearance from 
399 to 623 ml/min. In this study the neostigmine t/ 
(77.7 + 6.4 mean + SE) was 2-3 times as long as the slow 
disposition t (25.45 + 6.7 mean + SE) after intravenous 
injection (Calvey 1979), and the volume of distribution 
reported in the IV study was at least three times that after 
intramuscular injection in the present study. 
The volume of distribution of neostigmine was approximately 
equal to total body water. Distribution studies in experimental 
animals suggests that the drug is localized in extra- 
cellular fluid (Somani, 1975). The results of IM study are 
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consistent with this interpretation. Total body clearance of 
the drug was greater than glomerular filtration rate, and 
suggests tubular secretion or extensive metabolism (see also 
Chapter VI). Studies on the elimination of radioactivity in 
urine after intramuscular 
14C-neostigmine (Somani, et al., 1980) 
confirmed that the drug is partially metabolized in man. 
The proportion of the dose eliminated as unchanged neostigmine 
and its metabolites increased from approximately 447. at one hour 
to 827. at 24 hours. Neostigmine was eliminated predominantly 
during the first two hours only a further 47. of the dose was 
excreted as unchanged drug between two and twenty-four hours. 
Their results suggest that metabolism and biliary excretion of 
the drug may play significant roles in its elimination in man 
and that neostigmine may be preferable to pyridostigmine (or 
other cholinesterase inhibitors) when renal function is 
impaired. 
ORAL NEOSTIGMINE AND PYRIDOSTIGMINE, AND THE CORRELATION OF CLINICAL 
RESPONSE TO PLASMA PYRIDOSTIGMINE IN MYASTHENIA GRAVIS. 
When plasma levels of pyridostigmine were monitored in eight 
myasthenic patients who were stabilized on oral pyridostigmine 
bromide only, there was a widely different daily "d os age regime 
(see Chapter VI). Although the concentration of pyridostigmine 
in plasma varied, there was a direct relationship between the 
AUC and total daily dose of the drug (r - 0.95). These 
observations are in direct contrast to that for one myasthenic 
patients whose bioavailability of the drug was increased six- 
fold by doubling the dose of pyridostigmine bromide (Calvey et al., 1977). 
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Perhaps there is also an intrasubject variation in the absorp- 
tion of the drug. No such observation was noticed in the 
nine patients who were treated with both oral pyridostigmine 
i 
and neostigmine (r = -6480). Neostigmine was only detected 
in one of the nine patients (second group). It was 
suggested that there might be a drug-drug interaction between 
pyridostigmine and neostigmine during oral absorption, so 
the concurrent administration of oral pyridostigmine and 
neostigmine may not benefit the patients. A combination of 
IM and oral routes of these two quaternary amines may be 
more advantageous in the treatment of severe cases of 
myasthenia gravis. 
The pharmacokinetics of pyridostigmine are not entirely 
understood and there is no good reason to predict that a 
relationship between serum levels and clinical responses 
should exist. Previous studies by Chan and Calvey (1977) 
indicate that in four patients with typical electromyographic 
decrement in the adductor pollicis, there was a positive 
correlation between the concentration of pyridostigmine in 
plasma and the effect on neuromuscular transmission. The 
plasma concentration of pyridostigmine required to restore 
transmission to normal varied over a five-fold range, reflecting 
the variable severity of the disease. In another myasthenic 
patient with purely ocular symptoms they reported that there 
was a significant correlation between the plasma concentration 
of the drug and the diameter of the palpebral fissure. 
The present studies on plasma pyridostigmine concentration 
and global assessment of nine patients (Chapter VI) show 
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that there is a trend towards a positive correlation between 
global assessment of muscle power and plasma concentrations 
in five patients, of the remaining four patients, three showed 
correlation approaching significance at p<0.35, while one 
showed a negative correlation (Chapter Vl'page 35 1). In these 
studies, a wide variety of exercises (each testing particular 
muscle functions) was used to account for the possible 
variations in strength of different muscle groups in the 
patients. Such global assessment, together with clinical 
improvement of the patients could be quantified more rationally 
than most of those reported previously. From the present 
findings it is probable that the differential dosage requirement 
of pyridostigmine in myasthenia gravis were related to both 
inter-subject variation in drug disposition and different 
severity of the disease in eight of the nine patients studied. 
However, it is not possible to explain the negative correlation 
in the patient (patient six) who was also treated with 
amitriptyline for depression. 
Further work on the kinetics of neostigmine and 
pyridostigmine should be designed to elucidate whether the 
intersubject variation in plasma levels and the drugs is 
due to (a) a difference in the actual oral absorption of the 
Anti-ChE agents or (b) a difference in the elimination (i. e., 
metabolism or excretion) of the drugs. From a pharmacokinetic 
point of view, neostigmine may offer no better advantage over 
pyridostigmine in the long term pharmacotherapy of myasthenia 
gravis. This can be explained in terms of low bioavailability 
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(Chapter VI, Part I, page 13 0)and the shorter plasma half- 
life (ChapterslV and V) of neostigmine. These findings are 
also supported by other published work (Aquilonius et al., 1979 ; 
1980). A combination therapy of neostigmine and pyridostigmine 
may not be of advantageous as proven by the findings in 
Chapter Six (Part I). However, further study on this 
interaction between these two Anti-ChE agents at the absorption 
phase should also be of interest. 
-157- 
APPENDICES 
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APPENDIX 4.1 
PATIENT SEX AGE WEIGHT IV DOSE OF 
(YR) (KG) PYRIDOSTIGMINE 
BROMIDE (mg) 
1 F 22 64.42 3.362(36.2pg/kg) 
2 M 36 53.08 2.771 of 
3 M 34 76.66 4.0 " 
4 M 20 82.10 4.29 
5 F 41 79.83 4.17 of 
6 M 45 84.37 3.10 to 
7 F 16 59.42 3.84 Is 
8 M 50 73.48 4.88 of 
9 M 64 93.44 2.60 " 
10 M 23 49.9 2.32 of 
11 M 34 80.74 8.429(72.4pg/kg) 
12 M 29 67.59 7.056 
13 F 23 63.96 6.677 is 
14 F 19 62.14 6.488 to 
15 F 59 70.08 7.316 of 
16 M 55 71.44 7.458 is 
OTHER DRUGS 
CONCURRENTLY 
ADMINISTERED 
phenytoin 
sodium (300 
mg/day) and 
phenobarbitone 
(9mg/day) 
17 M 23 49.9 10.41(144.8pg/kg) 
18 M 45 84.37 17.6 
19 M 20 58.06 12.123 " 
20 M 31 87.09 18.181 " 
21 M 60 75.30 15.723 
22 F 56 75.75 15.817 " 
23 F 26 57.15 11.93 
Intravenous injection (IV) doses of pyridostigmine bromide and 
other data in 23 myasthenic patients. 
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APPENDIX 4.3 
BLOOD CONCE NTRATION OF PYRIDOSTIGMINE MEAN + SE 
ýA"'TJ NG (n$/ml) of SI X PATIENTS CONCENTRATION OF 
TIME SIX PATIENTS 
(min. ) 11 12 13 14 15 16 
0 0 0 0 0 0 0 0.0 + 0.0 
2 221 196 213 448 102 482 227.16 + 62.3 
3 - 119 114 376 500 279 227.60 + 74.5 
4 30 114 88 180 389 130 155.2 + 50.6 
5 34 97 75 155 205 112 113.0 + 24.6 
7 15 47 52 113 103 72 67.0 + 15.0 
10 15 17 36 47 7.7 70 43.6 + 10.6 
15 ND* 9 19 35 35 56 30.8 + 0.84 
20 ND 6 14 30 21 34 21.0 + 5.0 
30 ND ND 9 - 10 9 9.3 + 0.33 
40 ND ND ND 4.6 4.3 12 6.9 + 2.5 
50 ND ND ND ND ND 9 9.0 + 0.0 
60 ND 4 ND ND ND ND 4.0 + 0.0 
80 ND 3.6 ND ND ND 3 3.3 + 
100 ND 4 ND ND ND ND 4.0 + 0.29 
120 - ND ND ND ND ND - - 
140 - ND ND - ND 1.5 1.5 + 0.0 
160 ND 
*ND non-detectable 
Plasma concentration of pyridostigmine (ng/ml) 
in six surgical patients following an IV dose 
of 72.4pg (400 nmol/kg) as the bromide salt, over 
a period of time (2 to 140min. ). 
MISSING 
PRINT 
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APPENDIX 4.4 
BLOOD CONCENTRATION OF PYRIDOSTIGMINE (ug/ml) MEAN + SE 
SAMPLTNG CONCENTRATION 
TIME OF SEVEN PATIENTS 
(min. ) 17 18 19 20 21 22 23 (ng/ml ) 
0 0 0 0 0 0 0 0 
2 743 683 859 31 259 1034 218 546.7 + 376.1 
3 235 326 276 - 177 369 - 276.6 + 33.6 
4 207 307 184 61 93 155 138 163.6 + 30.5 
5 179 273 178 62 71 116 - 146.5 + 32.5 
6 - - - - - - 74 - - - 
7 163 247 176 102 64 - - 150.4 + 31.5 
8 - - - - - - 40 - - 
10 156 180 169 40 38 - 28 101.8 + 29.9 
12 - - - - - - 15.5 - - 
14 - - - - - - 16 - - 
15 - 139 146 34 29 21 - 73.8 + 28.1 
16 - - - - - - 13.2 - - 
18 - - - - - - 12.5 - - 
20 - 129 112 31 20 20 5.6 52.9 + 21.7 
30 84 - 88 - - 2.3 - 58.1 + 27.9 
40 70 96 80 19 19 1.4 - 47.5 + 15.9 
60 47 83 70 10 11 ND - 44.2 + 13.5 
80 - 77 63 - 1.5 ND - 47.1 + 23.0 
100 35 51 52 3.2 1.3 ND - 28.5 + 11.1 
120 - 44 38 ND ND ND - 38.0 + 1.6 
140 - 38 - - - ND - 38 + 0 
160 - 37 - - - ND - 37 + 0 
Plasma concentration of pyridostigmine (ng/mi) in 
seven surgic al patients following an IV dose of 
144.8 }ig/kg (800 nmol/kg) as the bromide salt, over 
a period of time (2 - 160mins. ). 
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APPENDIX 4.11 
Digital computer programe for bi-tri-exponential analysis of the 
, 
plasma profile of IV pyridostigmine. 
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APPENDIX 6.1 
The times pyridostigmine (pyr. ) and other drugs were taken. 
PATIENT 
NUMBER 
1 Pyr. 60mg 08.00 
prednisolone, 40mg 11.00 
Slow potassium 600mg 08.00 
600mg 18.00 
2 Pyr. 60mg 07.00,11.00,15.00,19.00,22.30 
Prednisolone 25mg alternate days. 
3 Pyr. 60mg 07.30, noon, 17.00 
4. Pyr. 120mg 06.00 
60mg 10.00,15.30,18.00 
5 Pyr. 120mg 06.00,18.00,22.00 
60mg 10.00, noon, 15.00 
6. Pyr. 120mg 06.00,10.15 
60mg 14.00,18.00 
7. Pyr. 120mg 07.50, noon, 17.00,22.00 
8. Pyr. 60mg 07.00, noon, 17.00,22.00 
-173- 
APPENDIX 6.2 
The times pyridostigmine (pyr. ), neostigmine (Neo. ), and other 
drugs were taken. 
PATIENT 
9 Pyr. 60mg 10.00,14.00,18.00,22.00 
Neo. 30mg 07.00,10.00,14.00,18.00,22.00 
10 Pyr. 60mg 06.30, 12.30, 15.30,18.30,23.00 
Neo. 30mg 06.30, 09.30, 15.30 
Neo. 15mg 12.30, 18.30, 21.00 
11 Pyr. 120mg 06.00, noon 
60mg 18.00,21.00 
Neo. 45mg 06.00 
Neo 30mg 09.00, noon, 15.15,18.00 
Neo. 15mg 21.00 
12 Pyr. 60mg 07.00,10.00, noon, 18.00,22.00 
Neo. 15mg 0700, noon, 16.00,22.00 
13 Pyr. 360mg (total daily dose) 
Neo. 30mg three hourly 
14 Pyr. 360mg (total dose) 
Neo. 30mg three hourly 
15 Pyr 60mg 07.30,15.00,22.00 
Neo. 30mg 07.30,10.30,14.00,16.00,19.00,22.00 
16 Pyr. 120mg 0100,09.00,11.00,13.00,15.00,17.00 
19.00,21.00,23.00 
Neo. 15mg 07.00 
Prednisolone 20mg alternate days 
17 Pyr. 90mg 06.30,09.00,11.30,14.00,15.45,17.45 
19.45,21.30,22.30 
Neo. 60mg 06.30,111.309 14.00,15.45,17.45,19.45, 
21.30. 
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APPENDIX 6.4 
Blood sample times and concentration of pyridostigmine and 
neostigmine, throughout the waking day (8.00am to 8.00pm). 
Numbers in brackets indicate the patient's number. 
(1) (2) 
TIME PYR. TIME PYR. 
(hr) n ml) hr n tnl) 
16.15 1.3 16.00 24 
18.00 2.2 18.00 36 
20.00 2.1 20.00 24 
09.00 12.4 08.00 28 
10.00 11.3 10.00 9 
12.00 8.3 12.00 28 
(3) (4) 
TIME PYR. TIME PYR. 
(hr) (na/ml) (hr) ml 
16.00 5.0 16.00 21.0 
18.00 11.0 18.00 27.0 
20.00 5.0 20.00 11.0 
09.00 14.0 08.00 36.0 
10.00 11.0 10.00 40.0 
12.00 11.0 12.00 25.0 
(5) (6) 
TIME PYR. TIME PYR. 
hr n ml hr n ml) 
16.00 27.5 16.00 40 
18.00 20.5 18.00 25 
20.00 64.5 20.00 30.5 
08.00 46.0 08.00 26.5 
10.00 46.0 09.00 29.0 
12.00 42.0 11.00 29.0 
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(7) (8) 
TIME PYR. TIME PYR. 
(hr) (n ml (hr) n ml) 
16.00 24.0 16.00 6.2 
18,00 28.5 18.00 17.2 
20.00 36.5 20.00 16.5 
08.00 39.0 08.00 18.6 
10.00 27.5 10.00 18.5 
12.00 33.0 20.00 23.0 
(9) (lo) 
TIME PYR. NEO. TIME PYR. NEO. 
(hr) n ml) n ml (hr) (n&/Ml) (n&/Ml) 
16.10 55 - 16.15 5- 
18.00 43 - 18.00 11 - 
20.00 54 - 20.00 5- 
08.00 14 - 09.00 14 - 
10.00 12.3 - 10.30 11 - 
12.00 61.5 - 12.00 11 - 
(11) (12) 
TIME PYR. NEO. TIME PYR. NEO. 
(hr) ml (na/ml) (hr) n ml (nit/ml) 
18.00 8.0 - 15.15 66 - 
20.00 8.0 - 17.15 144 - 
08.00 7- 19.00 59 - 
20.00 7- 08.40 69 - 
12.00 5.4 - 10.10 67.5 - 
14.00 15.3 - 12.00 50 - 
(13) (14) 
TIME PYR. NEO. TIME PYR. NEO. 
(hr) n ml) (na/ml) (hr) (u&/ml) n ml) 
16.00 -- 16.00 23 - 
18.00 16.2 - 18.00 26.5 - 
20.00 11.4 - 20.00 9.3 - 
08.00 5.5 - 08.00 13.4 - 
10.00 60.0 - 10.00 13.10 - 
12.00 35.0 - 12.00 14.0 - 
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(15) (16) 
TIME PYR. NEO. TIME PYR. NEO. 
(hr) (ng/ml) (nom (hr) n ml) (n ml) 
15.15 2.7 12.7 16.00 27 - 
17.15 12.2 10 18.00 36.5 - 
19.00 9.4 33 20.00 30.0 - 
08.40 18.6 13 08.00 14.0 - 
10.05 9.5 4.7 10.00 17.0 - 
12.00 4.5 5.5 11.50 27.4 - 
(17) 
r 
U 4r $ngl E0 ý, n (m_1) nQ=m1 
15.50 5.3 - 
18.00 5.0 - 
20.00 22 - 
08.00 28 - 
10.00 28.5 - 
11.50 23.5 - 
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APPENDIX 6.5 
Plasma concentration of pyridostigmine and performance in the 
test routine. 
PATIENT TIME PLASMA PYR. RANK SCORE SCALE SCORE 
hr n ml 
1 16.15 1.3 7.5 18.4 
18.00 2.2 20.5 44.6 
20.00 2.1 14.0 31.2 
09.00 12.4 21.0 48.8 
10.00 11.3 31.0 61.2 
12.00 8.3 26 51.2 
MEAN + SD 6.28 + 5.021 20 + 8.37 42.57 + 15.36 
2 16.00 24 19.5 31.9 
18.00 36 18.5 34.1 
20.00 24 7.5 12.5 
08.00 28 30.0 57.9 
10.00 9 13.0 25.5 
12.00 28 31.0 55.5 
MEAN + SD 25.5+8.80 20 + 9.186 36.23 + 17.56 
3 16.00 5.0 14.5 41.4 
18.00 11.0 23.0 56.1 
20.00 5.0 17.0 47.8 
09.00 14.0 13.0 38.9 
10.00 11.0 28.0 64.3 
12.00 11.0 24.0 61.1 
MEAN + SD 9.5 + 3.67 20 + 6.09 51.6 + 10.5 
4 16.00 21.0 21.0 35.24 
18.00 27.0 14.5 24.73 
20.00 11.0 14.0 19.85 
08.00 36.0 20.5 38.5 
10.00 40.0 21.5 35.76 
i2.00 25.0 28.5 52.76 
MEAN + SD 26.67 + 10.45 20 + 5.33 34.48 + 11.50 
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PATIENT TIME PLASMA PYR. RANK SCORE SCALE SCORE 
__ 
(hr) (ng/ml) 
5 16.00 27.5 14.5 39.9 
18.00 20.5 15.0 28.6 
20.00 64.5 23.0 40.8 
08.00 46.0 16.5 31.4 
10.00 46.0 28.0 59.7 
12.00 42.0 23.0 45.3 
MEAN + SD 41.08 +15.53 20 + 5.47 40.45 + 12.23 
6 16.00 40 14.0 29.7 
18.00 25 27.0 52.5 
20.00 30.5 14.0 23.8 
08.00 26.5 21.5 40.3 
09.00 29.0 20.5 46.4 
11.00 29.0 23.0 51.2 
MEAN + SD 30 + 5.28 20 + 5.15 40.65 + 11.74 
7 16.00 24 14.5 32.5 
18.00 28.5 16.5 34.4 
20.00 26.5 25 56.2 
08.00 39 18.5 39.7 
10.00 27.5 21.5 43.9 
12.00 33 24 43.4 
MEAN + SD 31.41 + 5.74 20 + 4.19 41.68 + 8.5 
8 16.00 6.2 14.5 26.7 
18.00 17.2 17.5 29.2 
20.00 16.5 19.0 30.3 
08.00 18.6 21.0 43.7 
10.00 18.5 22.0 45.5 
20.00 23.0 25.5 43.4 
MEAN + SD 16.67+ 5.6 20 + 3.87 36.47 + 8.58 
16 16.00 27.0 20 52.5 
18.00 36.5 26.5 66.5 
20.00 30.0 15.0 37.3 
08.00 14.0 8.5 17.8 
10.00 11.0 23.5 51.9 
11.00 27.4 26.5 55.6 
MEAN + SD 24.32+9.81 20 + 7.13 46.93 + 17.06 
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Digital computer program for regression analysis between global 
assessment of muscle power and plasma concentration of 
pyridostigmine, after oral administration. 
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